Menu
 
Research menu
Jump to menu

Publications:  Prof Gavin Giovannoni

Noyce AJ, Schrag A, Masters JM et al. (2016) . Subtle motor disturbances in PREDICT-PD participants.J Neurol Neurosurg Psychiatry
10.1136/jnnp-2016-314524
von Kutzleben S, Pryce G, Giovannoni G et al. (2016) . Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.Immunology
10.1111/imm.12696
Arroyo González R, Kita M, Crayton H et al. (2016) . Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.Mult Scler
10.1177/1352458516677589
Pakpoor J, Wotton CJ, Schmierer K et al. (2016) . Gender identity disorders and multiple sclerosis risk: A national record-linkage study. Mult Scler. vol. 22, 1759-1762.
10.1177/1352458515627205
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11114
Baker D, Anandhakrishnan A, Tuite-Dalton KA et al. (2016) . How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis.Mult Scler Relat Disord vol. 10, 127-133.
10.1016/j.msard.2016.09.007
Arnold DL, Fisher E, Brinar VV et al. (2016) . Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.Neurology vol. 87, (14) 1464-1472.
10.1212/WNL.0000000000003169
Giovannoni G (2016) . Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES.Mult Scler vol. 22, (11) 1397-1400.
10.1177/1352458516650737
Giovannoni G, Butzkueven H, Dhib-Jalbut S et al. (2016) . Brain health: time matters in multiple sclerosis.Mult Scler Relat Disord vol. 9 Suppl 1, S5-S48.
10.1016/j.msard.2016.07.003
Giovannoni G, Kappos L, Gold R et al. (2016) . Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.Mult Scler Relat Disord vol. 9, 36-46.
10.1016/j.msard.2016.05.010
Giovannoni G (2016) . Time and brain health both matter in multiple sclerosis.Mult Scler Relat Disord vol. 9 Suppl 1, S1-S3.
10.1016/j.msard.2016.07.004
Chitnis T, Ghezzi A, Bajer-Kornek B et al. (2016) . Pediatric multiple sclerosis: Escalation and emerging treatments.Neurology vol. 87, (9 Suppl 2) S103-S109.
10.1212/WNL.0000000000002884
Matthews PM, Roncaroli F, Waldman A et al. (2016) . A practical review of the neuropathology and neuroimaging of multiple sclerosis.Pract Neurol vol. 16, (4) 279-287.
10.1136/practneurol-2016-001381
Feys P, Giovannoni G, Dijsselbloem N et al. (2016) . The importance of a multi-disciplinary perspective and patient activation programmes in MS management.Mult Scler vol. 22, (2 Suppl) 34-46.
10.1177/1352458516650741
Rodríguez Cruz PM, Matthews L, Boggild M et al. (2016) . Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom.JAMA Neurology vol. 73, (8) 954-954.
10.1001/jamaneurol.2016.1463
http://qmro.qmul.ac.uk/xmlui/handle/123456789/15351
Gold R, Radue EW, Giovannoni G et al. (2016) . Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.BMC Neurol vol. 16,
10.1186/s12883-016-0635-y
Giovannoni G (2016) . Why do you have to be lucky to get the MS treatment you deserve?.Mult Scler Relat Disord vol. 8, A3-A4.
10.1016/j.msard.2016.06.004
Ziemssen T, Derfuss T, de Stefano N et al. (2016) . Optimizing treatment success in multiple sclerosis.J Neurol vol. 263, (6) 1053-1065.
10.1007/s00415-015-7986-y
Gold R, Giovannoni G, Phillips JT et al. (2016) . Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.Neurol Ther vol. 5, (1) 45-57.
10.1007/s40120-016-0042-8
Inshasi JS, Al Jumah M, Alroughani R et al. (2016) . Alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis demonstrate durable slowing of brain volume loss over 5 years with most not receiving treatment for 4 years-CARE-MS I and II extension study. MULTIPLE SCLEROSIS JOURNAL. vol. 22, NP7-NP7.
Fernandez O, Giovannoni G, Fox RJ et al. (2016) . Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users with low clinical disease activity-Integrated analysis of the phase 3 define and confirm studies. MULTIPLE SCLEROSIS JOURNAL. vol. 22, NP3-NP3.
Phillips JT, Bar-Or A, Gold R et al. (2016) . Efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing- remitting multiple sclerosis using a composite measure of disability-Integrated analysis of the phase 3 define and confirm studies. MULTIPLE SCLEROSIS JOURNAL. vol. 22, NP3-NP4.
Freedman MS, Kappos L, Cree BAC et al. (2016) . Efficacy of fingolimod on no evidence of disease activity (NEDA)-4 in pooled FREEDOMS and FREEDOMS II studies by subgroups of baseline characteristics. MULTIPLE SCLEROSIS JOURNAL. vol. 22, NP21-NP21.
Giovannoni G (2016) . How long is the presymptomatic phase of multiple sclerosis?.Mult Scler Relat Disord vol. 7, 12-13.
10.1016/j.msard.2016.02.010
Giovannoni G (2016) . Is multiple sclerosis a length-dependent central axonopathy.IRISH JOURNAL OF MEDICAL SCIENCE vol. 185, S176-S176.
Giovannoni G, Butzkueven H, Dhib-Jalbut S et al. (2016) . Time matters in multiple sclerosis-International consensus policy recommendations on diagnosis, management, and treatment access. MULTIPLE SCLEROSIS JOURNAL. vol. 22, NP16-NP16.
Hegen H, Adrianto I, Lessard CJ et al. (2016) . Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.Neurol Neuroimmunol Neuroinflamm vol. 3, (2)
10.1212/NXI.0000000000000202
Giovannoni G (2016) . Gavin Giovannoni on why time matters in multiple sclerosis.Neurodegener Dis Manag vol. 6, (2) 77-79.
10.2217/nmt.16.3
Raftopoulos R, Hickman SJ, Toosy A et al. (2016) . Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.Lancet Neurol vol. 15, (3) 259-269.
10.1016/S1474-4422(16)00004-1
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11119
Topping J, Dobson R, Lapin S et al. (2016) . The effects of intrathecal rituximab on biomarkers in multiple sclerosis.Mult Scler Relat Disord vol. 6, 49-53.
10.1016/j.msard.2016.01.001
Montalban X, Hemmer B, Rammohan KW et al. (2016) . A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 17-17.
Davis A, Dobson R, Kaninia S et al. (2016) . Atraumatic needles for lumbar puncture: why haven't neurologists changed?.Pract Neurol vol. 16, (1) 18-22.
10.1136/practneurol-2014-001055
http://qmro.qmul.ac.uk/xmlui/handle/123456789/10032
Radue EW, Sprenger T, Vollmer T et al. (2016) . Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.Eur J Neurol vol. 23, (2) 412-415.
10.1111/ene.12922
Wolinsky JS, Arnold D, Bar-Or A et al. (2016) . Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 63-64.
Nourbakhsh B, Gnanapavan S, Giovannoni G et al. (2016) . Serum neurofilament light chain levels are associated with cognitive and disability measures in patients with very early MS: a longitudinal study. MULTIPLE SCLEROSIS JOURNAL. vol. 22, 9-9.
Disanto G, Adiutori R, Dobson R et al. (2016) . Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY vol. 87, (2) 126-129.
10.1136/jnnp-2014-309690
Disanto G, Adiutori R, Dobson R et al. (2016) . Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.J Neurol Neurosurg Psychiatry vol. 87, (2) 126-129.
10.1136/jnnp-2014-309690
Dobson R, Ramagopalan S, Topping J et al. (2016) . A Risk Score for Predicting Multiple Sclerosis.PLoS One vol. 11, (11)
10.1371/journal.pone.0164992
Noyce A, Bestwick J, Mencacci N et al. (2015) . PREDICT-PD: Identifying Risk of Parkinson's disease in the Community. MOVEMENT DISORDERS. vol. 30, 1989-1989.
Masters JM, Bestwick J, Warner TT et al. (2015) . Systematic review and meta-analysis of salivary protein concentration in Parkinson's disease.Mov Disord vol. 30, (14) 1971-1972.
10.1002/mds.26462
Coles A, Giovannoni G, Moreau T et al. (2015) . ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 86,
10.1136/jnnp-2015-312379.106
Thomson A, Davis A, Paterson A et al. (2015) . DESIGNING AN INFORMATION RESOURCE TO EXPLAIN DIAGNOSTIC LUMBAR PUNCTURE AND PROMOTE BEST PRACTICE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 86,
10.1136/jnnp-2015-312379.3
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11116
Masters J, Noyce A, Giovannoni G et al. (2015) . ELEVATED SALIVARY DJ-1 IN PARKINSON'S DISEASE IS ASSOCIATED WITH ALTERED SALIVARY SECRETION. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 86,
10.1136/jnnp-2015-312379.23
Giovannoni G, Gold R, Fox RJ et al. (2015) . Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.CLINICAL THERAPEUTICS vol. 37, (11) 2543-2551.
10.1016/j.clinthera.2015.09.011
Chataway J, Chandran S, Miller D et al. (2015) . THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A MULTI-ARM, MULTI-CENTRE TRIAL OF NEUROPROTECTION. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 86,
10.1136/jnnp-2015-312379.105
Masters JM, Noyce AJ, Warner TT et al. (2015) . Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity.Parkinsonism Relat Disord vol. 21, (10) 1251-1255.
10.1016/j.parkreldis.2015.07.021
Arnold DL, Traboulsee A, Cohen JA et al. (2015) . Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS I with the majority of patients treatment-free for 4 years. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 568-569.
Traboulsee A, Cohen JA, Coles AJ et al. (2015) . Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS II with most patients free from treatment for 4 years. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 570-571.
Montalban X, Giovannoni G, Hartung H-P et al. (2015) . Alemtuzumab improves disability outcomes versus subcutaneous interferon beta-1a in CARE-MS I and II patients with active relapsing multiple sclerosis using the novel SAD-plus endpoint. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 588-588.
Barkhof F, Cohen JA, Coles AJ et al. (2015) . Alemtuzumab slows brain volume loss over 5 years in patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE MS I and II extension study. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 44-45.
Havrdova E, Gold R, Fox RJ et al. (2015) . Association between no evidence of disease activity (NEDA) and long-term clinical efficacy of delayed-release dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis from the phase 3 study, ENDORSE. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 256-257.
Raghupathi K, Pace A, Giovannoni G et al. (2015) . Baseline cognitive function predicts clinical disability progression in an integrated RRMS clinical trial database. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 121-122.
Phillips JT, Selmaj K, Gold R et al. (2015) . Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.Int J MS Care vol. 17, (5) 236-243.
10.7224/1537-2073.2014-069
Maggiore C, Giovannoni G, Martin JE et al. (2015) . Combinatorial antibody phage display libraries constructed from B-cells infiltrating brain tissue of people with progressive multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 464-465.
Moreau T, Arroyo Gonzalez R, Hartung H-P et al. (2015) . Disability improvement with alemtuzumab is associated with durable improvement on functional assessment in multiple sclerosis scores over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 564-565.
Giovannoni G, Berkovich R, Fernandez O et al. (2015) . Durable improvement in expanded disability status scale functional systems scores over 4 years with alemtuzumab despite a majority of patients not receiving treatment since year 1. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 571-572.
Kappos L, Havrdova E, Giovannoni G et al. (2015) . Effect of daclizumab HYP versus intramuscular interferon beta-1a on no evidence of disease activity in patients with relapsing-remitting multiple sclerosis: analysis of the DECIDE study. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 22-22.
Montalban X, Hemmer B, Rammohan K et al. (2015) . Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 781-782.
Fernandez O, Giovannoni G, Fox RJ et al. (2015) . Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users with low clinical disease activity: integrated analysis of the phase 3 DEFINE and CONFIRM studies. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 687-687.
Bar-Or A, Gold R, Fox RJ et al. (2015) . Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis using a composite measure of disability: integrated analysis of the phase 3 DEFINE and CONFIRM studies. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 303-304.
Giovannoni G, Gold R, Phillips JT et al. (2015) . Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post-hoc analysis of the phase 3 DEFINE and CONFIRM studies according to baseline cognitive function. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 252-253.
Gold R, Giovannoni G, Phillips JT et al. (2015) . Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post-hoc analysis of the phase 3 DEFINE and CONFIRM studies according to baseline disability. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 263-264.
Freedman MS, Kappos L, Cree BAC et al. (2015) . Efficacy of fingolimod on NEDA-4 in pooled FREEDOMS and FREEDOMS II studies by subgroups of baseline characteristics. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 301-302.
Giovannoni G, Brex P, Sumra M et al. (2015) . Glatiramer acetate slows disability progression - results from a 6-year analysis of the UK Risk Sharing Scheme. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 800-801.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11118
Marantz J, Gold R, Giovannoni G et al. (2015) . Longer-term follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 263-263.
Wiendl H, Giovannoni G, Greenberg S et al. (2015) . Lymphocyte counts in patients receiving daclizumab HYP in DECIDE. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 266-267.
Koch MW, Steinerman JR, Knappertz V et al. (2015) . MRI measures and disability progression in PPMS: analysis of the PROMiSe clinical trial dataset. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 46-46.
Gold J, Giovannoni G, Marta MC et al. (2015) . Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 162-162.
Vermersch P, Giovannoni G, Cohen JA et al. (2015) . Quality of life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 621-621.
Giovannoni G, Kappos L, Gold R et al. (2015) . Safety and tolerability of daclizumab HYP in patients with relapsing-remitting multiple sclerosis: an integrated analysis of six clinical studies. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 254-254.
Gnanapavan S, Grant D, Morant S et al. (2015) . Serum neurofilament light chain levels are associated with brain atrophy in early MS - analysis from the randomized controlled phase II trial of riluzole in early MS. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 355-356.
Kappos L, Bar-Or A, Cree B et al. (2015) . Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 317-318.
Raftopoulos R, Rangarajan A, Chen C-L et al. (2015) . Sodium channel blockade with phenytoin has a neuroprotective effect on the ganglion cell complex after acute optic neuritis. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 273-274.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12094
Arroyo Gonzalez R, Moreau T, Hartung H-P et al. (2015) . Sustained reduction in disability with alemtuzumab is associated with durable quality-of-life improvement on SF-36 over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 600-601.
Giovannoni G, Butzkueven H, Dhib-Jalbut S et al. (2015) . Time matters in multiple sclerosis - international consensus recommendations on diagnosis, management and access to treatment. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 801-802.
Scolding N, Barnes D, Cader S et al. (2015) . Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.Pract Neurol vol. 15, (4) 273-279.
10.1136/practneurol-2015-001139
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11980
Kappos L, Radue EW, Comi G et al. (2015) . Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.Neurology vol. 85, (1) 29-39.
10.1212/WNL.0000000000001706
Kuhle J, Disanto G, Dobson R et al. (2015) . Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.Mult Scler vol. 21, (8) 1013-1024.
10.1177/1352458514568827
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7011
Giovannoni G, Turner B, Gnanapavan S et al. (2015) . Is it time to target no evident disease activity (NEDA) in multiple sclerosis?.Mult Scler Relat Disord vol. 4, (4) 329-333.
10.1016/j.msard.2015.04.006
http://qmro.qmul.ac.uk/xmlui/handle/123456789/8421
Marta M, Santos E, Coutinho E et al. (2015) . The role of infections in Behçet disease and neuro-Behçet syndrome.Autoimmun Rev vol. 14, (7) 609-615.
10.1016/j.autrev.2015.02.009
http://qmro.qmul.ac.uk/xmlui/handle/123456789/14909
Fernandez Fernandez O, Hartung H-P, LaGanke C et al. (2015) . Alemtuzumab has a durable effect on disability improvement in treatment-naive patients with relapsing-remitting multiple sclerosis: a 4-year follow-up of CARE-MS I. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 824-824.
Arroyo Gonzalez R, Moreau T, Cohen JA et al. (2015) . Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients with inadequate efficacy response to prior therapy: 4-year follow-up of CARE-MS II. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 614-614.
Montalban X, Hemmer B, Rammohan K et al. (2015) . Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 706-706.
Thomson A, Davis A, Paterson A et al. (2015) . Designing an information resource to explain diagnostic lumbar puncture and promote best practice. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 491-492.
Wiendl H, Arnold DL, Hupperts RM et al. (2015) . Durable effect of alemtuzumab on disease activity in patients with relapsing-remitting multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 256-256.
Gold R, Giovannoni G, Phillips JT et al. (2015) . Long-term efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 27-27.
Giovannoni G, Havrdova E, Gold R et al. (2015) . Long-term follow-up of the effect of delayed-release dimethyl fumarate on No Evidence of Disease Activity in patients with multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 479-479.
Pryce G, Riddall DR, Selwood DL et al. (2015) . Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.J Neuroimmune Pharmacol vol. 10, (2) 281-292.
10.1007/s11481-014-9575-8
Raftopoulos R, Hickman S, Toosy A et al. (2015) . Neuroprotection with phenytoin in acute optic neuritis: results of a phase II randomised controlled trial. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 48-48.
Noyce AJ, Mencacci NE, Schrag A et al. (2015) . Web-based assessment of Parkinson's prodromal markers identifies GBA variants.Mov Disord vol. 30, (7) 1002-1003.
10.1002/mds.26249
Absoud M, Gadian J, Hellier J et al. (2015) . Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE).BMJ Open vol. 5, (5)
10.1136/bmjopen-2015-008312
Rieckmann P, Boyko A, Centonze D et al. (2015) . Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.Mult Scler Relat Disord vol. 4, (3) 202-218.
10.1016/j.msard.2015.02.005
Lu CH, Macdonald-Wallis C, Gray E et al. (2015) . Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.Neurology vol. 84, (22) 2247-2257.
10.1212/wnl.0000000000001642
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7441
Lu CH, Petzold A, Topping J et al. (2015) . Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.J Neurol Neurosurg Psychiatry vol. 86, (5) 565-573.
10.1136/jnnp-2014-307672
Thomson A, Rivas C, Giovannoni G (2015) . Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities.BMC Health Serv Res vol. 15,
10.1186/s12913-015-0773-8
Kuhle J, Disanto G, Lorscheider J et al. (2015) . Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.Neurology vol. 84, (16) 1639-1643.
10.1212/WNL.0000000000001491
McCarthy CL, Giovannoni G, Coles AJ (2015) . Timing is everything in the treatment of multiple sclerosis.BMJ Case Rep vol. 2015,
10.1136/bcr-2014-208960
Elkins J, Sheridan J, Amaravadi L et al. (2015) . CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.Neurol Neuroimmunol Neuroinflamm vol. 2, (2)
10.1212/NXI.0000000000000065
Kappos L, Giovannoni G, Gold R et al. (2015) . Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.Eur J Neurol vol. 22, (4) 664-671.
10.1111/ene.12624
Marques IB, Flanagan S, Noble H et al. (2015) . Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse.Neurol Neuroimmunol Neuroinflamm vol. 2, (2)
10.1212/NXI.0000000000000074
http://qmro.qmul.ac.uk/xmlui/handle/123456789/6959
Kuhle J, Gaiottino J, Leppert D et al. (2015) . Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome.J Neurol Neurosurg Psychiatry vol. 86, (3) 273-279.
10.1136/jnnp-2013-307454
Giovannoni G (2015) . Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis--yes.Mult Scler vol. 21, (2) 134-136.
10.1177/1352458514566261
Giovannoni G, de Jong B, Derfuss T et al. (2015) . A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.Mult Scler Relat Disord vol. 4, (1) 83-84.
10.1016/j.msard.2014.09.215
Gnanapavan S, Giovannoni G (2015) . Developing Biomarkers for MS.Curr Top Behav Neurosci vol. 26, 179-194.
10.1007/7854_2014_362
http://qmro.qmul.ac.uk/xmlui/handle/123456789/6325
Biela A, Watkinson M, Meier UC et al. (2015) . Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy.Biosensors and Bioelectronics vol. 68, 660-667.
10.1016/j.bios.2015.01.060
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9710
Fine D, Dattani A, Moreira I et al. (2015) . Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?.Mult Scler Relat Disord vol. 4, (1) 88-91.
10.1016/j.msard.2014.11.007
Gold R, Giovannoni G, Phillips JT et al. (2015) . Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).Mult Scler vol. 21, (1) 57-66.
10.1177/1352458514537013
Gold J, Goldacre R, Maruszak H et al. (2015) . HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study.J Neurol Neurosurg Psychiatry vol. 86, (1) 9-12.
10.1136/jnnp-2014-307932
Giovannoni G, Baker D, Schmierer K (2015) . The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?.Mult Scler Relat Disord vol. 4, (1) 3-5.
10.1016/j.msard.2014.11.005
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11979
Marques IB, Giovannoni G, Marta M (2014) . Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept.BMC Neurol vol. 14,
10.1186/s12883-014-0237-5
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11263
Kita M, Fox R, Gold R et al. (2014) . Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies.CLINICAL THERAPEUTICS vol. 36, (12) 1958-1971.
10.1016/j.clinthera.2014.08.013
Arnold DL, Gold R, Kappos L et al. (2014) . Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.J Neurol vol. 261, (12) 2429-2437.
10.1007/s00415-014-7504-7
Shribman SE, Noyce AJ, Martin JE et al. (2014) . The distribution of alpha-synuclein in the enteric nervous system: An immunohistochemical study on colonic resections from 24 control and 4 Parkinson's disease patients. MOVEMENT DISORDERS. vol. 29, 1839-1839.
Gnanapavan S, Yousaf N, Heywood W et al. (2014) . Growth associated protein (GAP-43): cloning and the development of a sensitive ELISA for neurological disorders.J Neuroimmunol vol. 276, (1-2) 18-23.
10.1016/j.jneuroim.2014.07.008
Lublin FD, Cutter G, Giovannoni G et al. (2014) . Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.Mult Scler Relat Disord vol. 3, (6) 705-711.
10.1016/j.msard.2014.08.005
Nixon R, Bergvall N, Tomic D et al. (2014) . No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.Adv Ther vol. 31, (11) 1134-1154.
10.1007/s12325-014-0167-z
Pakpoor J, Goldacre R, Schmierer K et al. (2014) . Testicular hypofunction and multiple sclerosis: Cause or consequence? Reply.Ann Neurol vol. 76, (5) 765-766.
10.1002/ana.24275
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7243
Pakpoor J, Handel AE, Disanto G et al. (2014) . National survey of UK medical students on the perception of neurology.BMC Med Educ vol. 14,
10.1186/1472-6920-14-225
Dua P, Jacobson L, Church A et al. (2014) . Detection of antibodies against the N-methyl-D-aspartate receptor in a sub-group of patients diagnosed with Tourette's syndrome. JOURNAL OF NEUROIMMUNOLOGY. vol. 275, 98-98.
10.1016/j.jneuroim.2014.08.262
Sisay S, Rosello A, Henseleit K et al. (2014) . Unaltered frequency and functionality of CD56bright and CD56dim natural killer cells in untreated relapsing-remitting multiple sclerosis patients. JOURNAL OF NEUROIMMUNOLOGY. vol. 275, 46-46.
10.1016/j.jneuroim.2014.08.122
http://qmro.qmul.ac.uk/xmlui/handle/123456789/6655
Cooper R, Doshi A, Harris P et al. (2014) . IMMUNOCOMPETENT PML-AN IMMUNOLOGICAL SCOTOMA?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.112
Pakpoor J, Handel A, Disanto G et al. (2014) . SURVEY OF UK MEDICAL STUDENTS ON THE PERCEPTION OF NEUROLOGY. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.46
Schmierer K, Marta M, Turner BP et al. (2014) . THE USE OF MAGNETIC RESONANCE IMAGING (MRI) IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UK. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.131
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7245
Pakpoor J, Goldacre R, Schmierer K et al. (2014) . Testicular hypofunction and multiple sclerosis risk: a record-linkage study.Ann Neurol vol. 76, (4) 625-628.
10.1002/ana.24250
http://qmro.qmul.ac.uk/xmlui/handle/123456789/6339
Gnanapavan S, Hegen H, Khalil M et al. (2014) . Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders.Neurology vol. 83, (13) 1210-1216.
10.1212/WNL.0000000000000809
Giovannoni G, Baker D, Schmierer K (2014) . Simvastatin in patients with progressive multiple sclerosis.Lancet vol. 384, (9947)
10.1016/S0140-6736(14)61621-4
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11982
Pakpoor J, Nyein S, Disanto G et al. (2014) . A global analysis of the use of social media to discuss multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 334-335.
Pakpoor J, Goldacre R, Disanto G et al. (2014) . Alcohol Misuse Disorders and Multiple Sclerosis Risk.JAMA NEUROLOGY vol. 71, (9) 1188-+.
Pakpoor J, Goldacre R, Disanto G et al. (2014) . Alcohol misuse disorders and multiple sclerosis risk.JAMA Neurol vol. 71, (9) 1188-1189.
10.1001/jamaneurol.2014.1795
Pakpoor J, Goldacre R, Disanto G et al. (2014) . Alcohol-use disorders and multiple sclerosis risk: a national record-linkage study. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 148-149.
Sarda SP, Kita M, Fox RJ et al. (2014) . An interim analysis of quality of life in patients with relapsing-remitting multiple sclerosis treated with delayed-release dimethyl fumarate. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 413-414.
Giovannoni G, Gold R, Kappos L et al. (2014) . Delayed-release dimethyl fumarate and disability assessed by the multiple sclerosis functional composite: integrated analysis of DEFINE and CONFIRM. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 92-92.
Fernandez O, Giovannoni G, Fox RJ et al. (2014) . Efficacy of delayed-release dimethyl fumarate for RRMS in prior interferon users in the DEFINE and CONFIRM studies. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 96-96.
Disanto G, Dobson R, Pakpoor J et al. (2014) . Genetic predictors of multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 253-253.
Gold R, Giovannoni G, Phillips JT et al. (2014) . Long-term efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 95-96.
Giovannoni G, Gold R, Fox RJ et al. (2014) . Long-term follow-up of the effect of delayed-release dimethyl fumarate on no evident disease activity in patients with multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 44-45.
Amor S, van der Star BJ, Bosca I et al. (2014) . Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.Mult Scler vol. 20, (10) 1355-1362.
10.1177/1352458514521887
Guimond C, Lee JD, Ramagopalan SV et al. (2014) . Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors.MULTIPLE SCLEROSIS JOURNAL vol. 20, (9) 1182-1188.
10.1177/1352458513519179
Arnold DL, Arnold DL, Gold R et al. (2014) . Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.Journal of Neurology
10.1007/s00415-014-7412-x
Shribman S, Torsney KM, Noyce AJ et al. (2014) . A service development study of the assessment and management of fracture risk in Parkinson's disease.J Neurol vol. 261, (6) 1153-1159.
10.1007/s00415-014-7333-8
Gold R, Giovannoni G, Phillips JT et al. (2014) . Efficacy of Oral BG-12 (Dimethyl Fumarate) in Patients Newly Diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Analysis of DEFINE and CONFIRM. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 931-932.
Sadovnick AD, Lee JD, Ramagopalan SV et al. (2014) . Genetic and Environmental Risk Factors for Multiple Sclerosis among Iranian Immigrants in Canada. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 909-910.
Giovannoni G, Heesen C (2014) . Shared decision making in the evolving multiple sclerosis (MS) treatment landscape. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 1015-1015.
Kappos L, Bar-Or A, Cree B et al. (2014) . Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial. MULTIPLE SCLEROSIS JOURNAL. vol. 20, 927-928.
Giovannoni G, Gold R, Selmaj K et al. (2014) . Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.Lancet Neurol vol. 13, (5) 472-481.
10.1016/S1474-4422(14)70039-0
Havrdova E, Gold R, Fox RJ et al. (2014) . Delayed-release dimethyl fumarate and freedom from measured clinical and neuroradiologic disease activity in relapsing-remitting multiple sclerosis (RRMS) patients: integrated analysis of DEFINE and CONFIRM. JOURNAL OF NEUROLOGY. vol. 261, S304-S305.
Kappos L, Fox RJ, Gold R et al. (2014) . Delayed-release dimethyl fumarate and health-related quality of life (HRQoL) in relapsing-remitting multiple sclerosis (RRMS) patients according to prior therapy: integrated analysis of DEFINE and CONFIRM. JOURNAL OF NEUROLOGY. vol. 261, S306-S306.
Giovannoni G, Gold R, Fox RJ et al. (2014) . Delayed-release dimethyl fumarate and relapses requiring intravenous steroid use and MS-related hospitalizations: integrated analysis of the phase 3 DEFINE and CONFIRM studies. JOURNAL OF NEUROLOGY. vol. 261, S303-S303.
Fernandez O, Giovannoni G, Fox RJ et al. (2014) . Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis (RRMS) in "non-responders" to prior treatment with interferon beta. EUROPEAN JOURNAL OF NEUROLOGY. vol. 21, 25-25.
Fernandez O, Giovannoni G, Fox RJ et al. (2014) . Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis (RRMS) in "non-responders'' to prior treatment with interferon beta. JOURNAL OF NEUROLOGY. vol. 261, S19-S20.
Ramien C, Pachnio A, Sisay S et al. (2014) . Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort.Mult Scler vol. 20, (6) 751-753.
10.1177/1352458513509507
http://qmro.qmul.ac.uk/xmlui/handle/123456789/6643
Raffel J, Dobson R, Gafson A et al. (2014) . Multiple sclerosis therapy and Epstein-Barr virus antibody titres.Mult Scler Relat Disord vol. 3, (3) 372-374.
10.1016/j.msard.2013.12.004
Giovannoni G, Naismith RT (2014) . Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.Neurology vol. 82, (14) 1196-1197.
10.1212/WNL.0000000000000296
Havrdova E, Giovannoni G, Stefoski D et al. (2014) . Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.MULTIPLE SCLEROSIS JOURNAL vol. 20, (4) 464-470.
10.1177/1352458513502113
Gafson AR, Giovannoni G (2014) . CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age.Mult Scler Relat Disord vol. 3, (2) 143-146.
10.1016/j.msard.2013.10.005
Puentes F, Topping J, Kuhle J et al. (2014) . Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis.J Neurol Neurosurg Psychiatry vol. 85, (3) 274-278.
10.1136/jnnp-2013-305494
Disanto G, Sandve GK, Ricigliano VAG et al. (2014) . DNase hypersensitive sites and association with multiple sclerosis.HUMAN MOLECULAR GENETICS vol. 23, (4) 942-948.
10.1093/hmg/ddt489
Davis A, Dobson R, Kaninia S et al. (2014) . Change practice now! Using atraumatic needles to prevent post lumbar puncture headache.Eur J Neurol vol. 21, (2) 305-311.
10.1111/ene.12307
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12000
Giovannoni G, Radue EW, Havrdova E et al. (2014) . Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.J Neurol vol. 261, (2) 316-323.
10.1007/s00415-013-7196-4
Kappos L, Gold R, Arnold DL et al. (2014) . Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study.MULTIPLE SCLEROSIS JOURNAL vol. 20, (2) 243-252.
10.1177/1352458513507817
Dobson R, Rudick RA, Turner B et al. (2014) . Assessing treatment response to interferon-beta Is there a role for MRI?.NEUROLOGY vol. 82, (3) 248-254.
10.1212/WNL.0000000000000034
Dobson R, Rudick RA, Turner B et al. (2014) . Assessing treatment response to interferon-β: is there a role for MRI?.Neurology vol. 82, (3) 248-254.
10.1212/WNL.0000000000000036
Noyce AJ, Nagy A, Acharya S et al. (2014) . Bradykinesia-akinesia incoordination test: validating an online keyboard test of upper limb function.PLoS One vol. 9, (4)
10.1371/journal.pone.0096260
Giovannoni G (2014) . Cerebrospinal fluid analysis.Handb Clin Neurol vol. 122, 681-702.
10.1016/B978-0-444-52001-2.00029-7
Pryce G, Visintin C, Ramagopalan SV et al. (2014) . Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.FASEB J vol. 28, (1) 117-130.
10.1096/fj.13-239442
Al-Izki S, Pryce G, Hankey DJ et al. (2014) . Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.Brain vol. 137, (Pt 1) 92-108.
10.1093/brain/awt324
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9650
Baker D, Pepper G, Yauner F et al. (2014) . MSer - A new, neutral descriptor for someone with multiple sclerosis.Mult Scler Relat Disord vol. 3, (1) 31-33.
10.1016/j.msard.2013.06.010
Noyce AJ, Bestwick JP, Silveira-Moriyama L et al. (2014) . PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results.JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY vol. 85, (1) 31-37.
10.1136/jnnp-2013-305420
Disanto G, Dobson R, Pakpoor J et al. (2014) . The refinement of genetic predictors of multiple sclerosis.PLoS One vol. 9, (5)
10.1371/journal.pone.0096578
Pryce G, Cabranes A, Fernández-Ruiz J et al. (2013) . Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.Mult Scler vol. 19, (14) 1896-1904.
10.1177/1352458513485982
Kuhle J, Malmeström C, Axelsson M et al. (2013) . Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.Acta Neurol Scand vol. 128, (6) e33-e36.
10.1111/ane.12151
Hadavi S, Giovannoni G, Dobson R (2013) . A service development audit of fampridine use in ms.J Neurol Neurosurg Psychiatry vol. 84, (11)
10.1136/jnnp-2013-306573.178
Dobson R, Topping J, Davis A et al. (2013) . Cerebrospinal fluid and urinary biomarkers in multiple sclerosis.ACTA NEUROLOGICA SCANDINAVICA vol. 128, (5) 321-327.
10.1111/ane.12119
Shribman S, Davis A, Vella N et al. (2013) . Heavy metal toxicity: lessons from a case of simultaneous occupational exposure to manganese and mercury.J Neurol Neurosurg Psychiatry vol. 84, (11)
10.1136/jnnp-2013-306573.126
Gafson A, Worthington V, Lakdawala N et al. (2013) . Neutralising antibodies to interferon-Beta predict conversion to secondary progressive multiple sclerosis in patients with multiple sclerosis.J Neurol Neurosurg Psychiatry vol. 84, (11)
10.1136/jnnp-2013-306573.176
Hadavi S, Shribman S, Nagy A et al. (2013) . The bradykinesia-akinesia incoordination test: a simple objective test in multiple sclerosis.J Neurol Neurosurg Psychiatry vol. 84, (11)
10.1136/jnnp-2013-306573.184
Dobson R, McMillan A, Kung K et al. (2013) . Think outside the box, collapse the box, and take a sharp knife to it!.J Neurol Neurosurg Psychiatry vol. 84, (11)
10.1136/jnnp-2013-306573.173
Dobson R, Topping J, Ramagopalan S et al. (2013) . Towards an endophenotype in multiple sclerosis.J Neurol Neurosurg Psychiatry vol. 84, (11)
10.1136/jnnp-2013-306573.31
Handel AE, Sandve GK, Disanto G et al. (2013) . Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression.BMC MEDICAL GENOMICS vol. 6, Article ARTN 45,
10.1186/1755-8794-6-45
Kuhle J, Plattner K, Bestwick JP et al. (2013) . A comparative study of CSF neurofilament light and heavy chain protein in MS.Mult Scler vol. 19, (12) 1597-1603.
10.1177/1352458513482374
Leddy S, Hadavi S, McCarren A et al. (2013) . A novel internet-based method of capturing outcomes in multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 357-358.
Kuhle J, Stites T, Chen Y et al. (2013) . CSF neurofilament light chain levels are markedly reduced by fingolimod in relapsing multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 559-560.
Hutchinson M, Gold R, Fox RJ et al. (2013) . Clinical efficacy of BG-12 (dimethyl fumarate) for relapsing remitting multiple sclerosis according to prior therapy: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 235-235.
Pakpoor J, Pakpoor J, Disanto G et al. (2013) . Cyt.lovirus and multiple sclerosis risk: a systematic review and meta-analysis. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 154-155.
Kappos L, Radue E-W, Comi G et al. (2013) . Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO). MULTIPLE SCLEROSIS JOURNAL. vol. 19, 50-51.
Gold R, Giovannoni G, Phillips JT et al. (2013) . Effect of BG-12 (dimethyl fumarate) in newly diagnosed relapsing remitting multiple sclerosis (RRMS) patients from the DEFINE and CONFIRM studies. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 453-454.
Havrdova E, Gold R, Fox RJ et al. (2013) . Effect of BG-12 (dimethyl fumarate) on freedom from measured clinical and neuroradiological disease activity over time in patients with relapsing remitting multiple sclerosis: results from the phase 3 studies. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 211-212.
Havrdova E, Bates D, Galetta S et al. (2013) . Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 209-210.
Bergvall N, Nixon R, Tomic D et al. (2013) . Efficacy of oral fingolimod versus dimethyl fumarate on measures of freedom from disease activity in patients with multiple sclerosis, based on indirect comparisons of phase 3 trials. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 519-519.
Giovannoni G, Mikulskis A, McNeil M et al. (2013) . Evaluation of immunogenicity in multiple sclerosis patients continuously treated with daclizumab-HYP during the SELECT and SELECTION clinical trials. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 390-390.
Selmaj K, Gold R, Fox RJ et al. (2013) . Flushing and gastrointestinal tolerability events in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 dimethyl fumarate) in the phase 3 DEFINE and CONFIRM trials. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 221-221.
Kita M, Fox RJ, Gold R et al. (2013) . Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in the ENDORSE study. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 530-530.
Kuhle J, Dobson R, Bestwick JP et al. (2013) . Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 33-34.
Lublin F, Cutter G, Giovannoni G et al. (2013) . Natalizumab reduces the disabling amplitude of multiple sclerosis relapses and improves post-relapse residual disability. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 213-214.
Raftopoulos RE, Hickman S, Toosy A et al. (2013) . Optical coherence tomography (OCT), visual function and MRI measures in acute optic neuritis: baseline data from a clinical trial. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 8-9.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/9614
Bergvall N, Nixon R, Tomic D et al. (2013) . Predicting the efficacy of fingolimod versus dimethyl fumarate in patients with multiple sclerosis using a statistical modelling approach. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 519-520.
James E, Dobson R, Kuhle J et al. (2013) . The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis.Mult Scler vol. 19, (12) 1571-1579.
10.1177/1352458513489756
Gold J, Christensen T, Maruszak H et al. (2013) . Triggering role of viruses in multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 19, 32-32.
Orchard A, Giovannoni G, Langdon D (2013) . UK validation of the brief international assessment for multiple sclerosis (BICAMS). MULTIPLE SCLEROSIS JOURNAL. vol. 19, 203-203.
Leddy S, Hadavi S, McCarren A et al. (2013) . Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis.J Neurol vol. 260, (10) 2505-2510.
10.1007/s00415-013-7004-1
Disanto G, Handel AE, Damoiseaux J et al. (2013) . Vitamin D supplementation and antibodies against the Epstein-Barr virus in multiple sclerosis patients.Mult Scler vol. 19, (12) 1679-1680.
10.1177/1352458513494494
Disanto G, Hall C, Lucas R et al. (2013) . Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis.Mult Scler vol. 19, (10) 1355-1358.
10.1177/1352458513477231
Bar-Or A, Gold R, Kappos L et al. (2013) . Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.JOURNAL OF NEUROLOGY vol. 260, (9) 2297-2305.
10.1007/s00415-013-6954-7
Gnanapavan S, Grant D, Morant S et al. (2013) . Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS - Neurofilament as a Surrogate of Disease Progression.PLOS ONE vol. 8, (8) Article ARTN e70019,
10.1371/journal.pone.0070019
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11260
Dobson R, Ramagopalan S, Davis A et al. (2013) . Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude.J Neurol Neurosurg Psychiatry vol. 84, (8) 909-914.
10.1136/jnnp-2012-304695
Ramagopalan SV, Goldacre R, Disanto G et al. (2013) . Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: record-linkage studies.BMC Med vol. 11,
10.1186/1741-7015-11-171
http://qmro.qmul.ac.uk/xmlui/handle/123456789/4697
Handel AE, Sandve GK, Disanto G et al. (2013) . Vitamin D receptor ChIP-seq in primary CD4+ cells: Relationship to serum 25-hydroxyvitamin D levels and autoimmune disease.BMC Medicine vol. 11, (1)
10.1186/1741-7015-11-163
http://qmro.qmul.ac.uk/xmlui/handle/123456789/4680
Bolton C, Gates J, Giovannoni G (2013) . Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE).Inflamm Res vol. 62, (7) 659-667.
10.1007/s00011-013-0618-z
Gold R, Giovannoni G, Selmaj K et al. (2013) . Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.LANCET vol. 381, (9884) 2167-2175.
10.1016/S0140-6736(12)62190-4
Maggiore C, Giovannoni G, Martin J et al. (2013) . Construction of an antibody phage display library from B-cells infiltrating brain tissue of people with progressive multiple sclerosis.JOURNAL OF NEUROLOGY vol. 260, S39-S39.
Pakpoor J, Pakpoor J, Disanto G et al. (2013) . Cytomegalovirus and multiple sclerosis risk.J Neurol vol. 260, (6) 1658-1660.
10.1007/s00415-013-6912-4
Gold R, Giovannoni G, Phillips JT et al. (2013) . Effect of BG-12 (dimethyl fumarate) in newly diagnosed patients with relapsing-remitting multiple sclerosis from the DEFINE and CONFIRM studies.JOURNAL OF NEUROLOGY vol. 260, S51-S51.
Giovannoni G, Gold R, Selmaj K et al. (2013) . Efficacy and safety of daclizumab high-yield process (DAC HYP) treatment in relapsing-remitting multiple sclerosis: results from the SELECTION extension study.JOURNAL OF NEUROLOGY vol. 260, S50-S51.
Gnanapavan S, Ho P, Heywood W et al. (2013) . Progression in multiple sclerosis is associated with low endogenous NCAM.J Neurochem vol. 125, (5) 766-773.
10.1111/jnc.12236
Gemma C, Ramagopalan SV, Down TA et al. (2013) . Inactive or moderately active human promoters are enriched for inter-individual epialleles.Genome Biol vol. 14, (5)
10.1186/gb-2013-14-5-r43
http://qmro.qmul.ac.uk/xmlui/handle/123456789/4899
Giovannoni G, Gold R, Fox RJ et al. (2013) . An integrated analysis of relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations from the BG-12 (dimethyl fumarate) phase 3 define and confirm studies.Value Health vol. 16, (3) A101-A102.
10.1016/j.jval.2013.03.479
Dobson R, Giovannoni G (2013) . Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis.J Neurol vol. 260, (5) 1272-1285.
10.1007/s00415-012-6790-1
Christensen T, Giovannoni G (2013) . HERVs: have we been here before? (vol 18, pg 1670, 2012).MULTIPLE SCLEROSIS JOURNAL vol. 19, (6) 827-829.
10.1177/1352458513485051
Dobson R, Yarnall A, Noyce AJ et al. (2013) . Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes.Pract Neurol vol. 13, (2) 70-79.
10.1136/practneurol-2012-000435
Giovannoni G (2013) . ECTRIMS 2012: Treatment highlights.Mult Scler Relat Disord vol. 2, (2) 68-72.
10.1016/j.msard.2012.12.005
Hutchinson M, Bar-Or A, Fox RJ et al. (2013) . Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from Two Phase 3 Studies (DEFINE and CONFIRM). MULTIPLE SCLEROSIS JOURNAL. vol. 19, 682-683.
Comi G, Cook SD, Giovannoni G et al. (2013) . MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.JOURNAL OF NEUROLOGY vol. 260, (4) 1136-1146.
10.1007/s00415-012-6775-0
Disanto G, Watson CT, Meier UC et al. (2013) . Month of birth and thymic output.JAMA Neurol vol. 70, (4) 527-528.
10.1001/jamaneurol.2013.2116
http://qmro.qmul.ac.uk/xmlui/handle/123456789/6646
Dobson R, Giovannoni G, Ramagopalan S (2013) . The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude.J Neurol Neurosurg Psychiatry vol. 84, (4) 427-432.
10.1136/jnnp-2012-303934
Dobson R, Leddy SG, Gangadharan S et al. (2013) . Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems.BMJ Open vol. 3, (3)
10.1136/bmjopen-2012-002508
Pakpoor J, Giovannoni G, Ramagopalan SV (2013) . Epstein-Barr virus and multiple sclerosis: association or causation?.Expert Rev Neurother vol. 13, (3) 287-297.
10.1586/ern.13.6
Disanto G, Pakpoor J, Morahan JM et al. (2013) . Epstein-Barr virus, latitude and multiple sclerosis.Mult Scler vol. 19, (3) 362-365.
10.1177/1352458512451942
Dobson R, Ramagopalan SV, Giovannoni G (2013) . Genome-wide association studies: will we ever predict susceptibility to multiple sclerosis through genetics?.Expert Rev Neurother vol. 13, (3) 235-237.
10.1586/ern.13.13
Ramagopalan SV, Giovannoni G, Yeates DG et al. (2013) . Sex ratio of infectious mononucleosis and possible relevance to multiple sclerosis.Mult Scler vol. 19, (3) 359-361.
10.1177/1352458512450627
Havrdova E, Gold R, Fox R et al. (2013) . BG-12 (Dimethyl Fumarate) Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies. NEUROLOGY. vol. 80,
Hutchinson M, Gold R, Fox R et al. (2013) . Clinical Efficacy of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS) According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. NEUROLOGY. vol. 80,
Radue E-W, Gold R, Giovannoni G et al. (2013) . Daclizumab HYP Reduces the Evolution of New Gadolinium-Enhancing Lesions to T1-Black Holes: Results from the SELECT Study. NEUROLOGY. vol. 80,
Giovannoni G, Arnold D, Cohen J et al. (2013) . Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II). NEUROLOGY. vol. 80,
Kita M, Fox R, Gold R et al. (2013) . Effects of BG-12 (Dimethyl Fumarate) on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. NEUROLOGY. vol. 80,
10.1016/j.clinthera.2014.08.013
Mehta L, Giovannoni G, Radue E-W et al. (2013) . Efficacy of Daclizumab HYP Treatment in Patients with Highly Active Relapsing-Remitting Multiple Sclerosis: Results from the SELECT Study. NEUROLOGY. vol. 80,
Meltzer L, Selmaj K, Gold R et al. (2013) . Gastrointestinal Tolerability Events in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral BG-12 (Dimethyl Fumarate) in DEFINE and CONFIRM. NEUROLOGY. vol. 80,
Havrdova E, Giovannoni G, Stefoski D et al. (2013) . Proportion of Disease-Activity Free Patients with Relapsing-Remitting Multiple Sclerosis Following 1 Year of Treatment with Daclizumab High-Yield Process in the SELECT Study. NEUROLOGY. vol. 80,
Giovannoni G, Gold R, Fox R et al. (2013) . Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies. NEUROLOGY. vol. 80,
10.1016/j.clinthera.2015.09.011
Mehta D, Amaravadi L, Gold R et al. (2013) . Reversal of the Pharmacodynamic Effects of Daclizumab HYP Following Treatment Washout: Results from the SELECTION Study. NEUROLOGY. vol. 80,
Giovannoni G, Comi G, Cook S et al. (2013) . Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study. NEUROLOGY. vol. 80,
Kappos L, Bar-Or A, Cree B et al. (2013) . Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial. NEUROLOGY. vol. 80,
Giovannoni G, Gold R, Selmaj K et al. (2013) . The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results. NEUROLOGY. vol. 80,
Kappos L, Giovannoni G, Gold R et al. (2013) . Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis. NEUROLOGY. vol. 80,
Baker D, Lidster K, Al-Izki S et al. (2013) . Animal models of progressive disability in MS.IRISH JOURNAL OF MEDICAL SCIENCE vol. 182, S5-S6.
Pakpoor J, Disanto G, Gerber JE et al. (2013) . The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis.Mult Scler vol. 19, (2) 162-166.
10.1177/1352458512449682
Thompson AJ, Giovannoni G (2013) . Removal of access to alemtuzumab for patients with aggressive multiple sclerosis.BMJ-BRITISH MEDICAL JOURNAL vol. 346, Article ARTN f275,
10.1136/bmj.f275
Dobson R, Topping J, Giovannoni G (2013) . Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers.J Med Virol vol. 85, (1) 128-131.
10.1002/jmv.23446
Miao T, Raymond M, Bhullar P et al. (2013) . Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf.J Immunol vol. 190, (1) 58-65.
10.4049/jimmunol.1200868
Sisay S, Pryce G, Jackson SJ et al. (2013) . Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis.PLoS One vol. 8, (10)
10.1371/journal.pone.0076907
http://qmro.qmul.ac.uk/xmlui/handle/123456789/6281
Gaiottino J, Norgren N, Dobson R et al. (2013) . Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.PLoS One vol. 8, (9)
10.1371/journal.pone.0075091
Gnanapavan S, Giovannoni G (2013) . Neural cell adhesion molecules in brain plasticity and disease.Mult Scler Relat Disord vol. 2, (1) 13-20.
10.1016/j.msard.2012.08.002
Lidster K, Jackson SJ, Ahmed Z et al. (2013) . Neuroprotection in a novel mouse model of multiple sclerosis.PLoS One vol. 8, (11)
10.1371/journal.pone.0079188
http://qmro.qmul.ac.uk/xmlui/handle/123456789/10591
Christensen T, Giovannoni G (2012) . HERVs: have we been here before?.MULTIPLE SCLEROSIS JOURNAL vol. 18, (12) 1670-1672.
10.1177/1352458512469331
Noyce AJ, Bestwick JP, Silveira-Moriyama L et al. (2012) . Meta-analysis of early nonmotor features and risk factors for Parkinson disease.Ann Neurol vol. 72, (6) 893-901.
10.1002/ana.23687
Cohen JA, Coles AJ, Arnold DL et al. (2012) . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.LANCET vol. 380, (9856) 1819-1828.
10.1016/S0140-6736(12)61769-3
Furby J, Giovannoni G, Page R (2012) . A CASE OF UNIHEMISPHERIC PROGRESSIVE MULTIPLE SCLEROSIS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.148
Dobson R, Ramagopalan S, Giovannoni G (2012) . Bone health and multiple sclerosis.Mult Scler vol. 18, (11) 1522-1528.
10.1177/1352458512453362
Dobson R, Rudick RA, Giovannoni G (2012) . CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON beta: A SYSTEMATIC REVIEW AND META-ANALYSIS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.127
Raffel J, Hunt D, Topping J et al. (2012) . CLASSIFICATION OF JC VIRUS SEROSTATUS DEPENDS UPON ASSAY SELECTION: A COMPARISON OF BIOGEN AND HPA ASSAYS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2012-304200a.72
Kappos L, Gold R, Arnold DL et al. (2012) . EFFECTS OF BG-12 ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: FINDINGS FROM THE PHASE 3 DEFINE STUDY.VALUE IN HEALTH vol. 15, (7) A557-A557.
Beyan H, Down TA, Ramagopalan SV et al. (2012) . Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans.Genome Res vol. 22, (11) 2138-2145.
10.1101/gr.134304.111
Havrdova E, Gold R, Fox RJ et al. (2012) . RELAPSES REQUIRING INTRAVENOUS STEROIDS AND MULTIPLE SCLEROSIS-RELATED HOSPITALIZATIONS: FINDINGS FROM THE PHASE 3 DEFINE AND CONFIRM STUDIES.VALUE IN HEALTH vol. 15, (7) A546-A546.
Raftopoulos RE, Hickman S, Toosy A et al. (2012) . A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 442-443.
Pakpoor J, Disanto G, Lacey MV et al. (2012) . Breastfeeding and multiple sclerosis relapses: a meta-analysis.J Neurol vol. 259, (10) 2246-2248.
10.1007/s00415-012-6553-z
Davis A, Dobson R, Espasandin M et al. (2012) . Cerebrospinal fluid biomarkers as outcome measures in clinical trials of MS: The significance of post lumbar puncture headaches. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 237-238.
Bar-Or A, Fox RJ, Gold R et al. (2012) . Clinical effects of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 191-191.
Radue EW, Gold R, Giovannoni G et al. (2012) . Daclizumab HYP monotherapy reduces black holes and T2 burden of disease in relapsing-remitting multiple sclerosis: results of the SELECT trial. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 193-194.
Giovannoni G, Radue EW, Havrdova E et al. (2012) . Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: results from the SELECT study. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 189-189.
Arnold DL, Gold R, Kappos L et al. (2012) . Effects of BG-12 on magnetic resonance imaging and magnetisation transfer ratio outcomes in relapsing-remitting multiple sclerosis: findings from the phase 3 DEFINE study. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 214-215.
Pakpoor J, Disanto G, Meier UC et al. (2012) . Epstein-Barr virus seroprevalence in multiple sclerosis patients: a systematic review and meta-analysis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 368-369.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7012
Giovannoni G, Stefoski D, Umans K et al. (2012) . Increase in proportion of patients free from disease activity following 1 year of treatment with daclizumab high-yield process in relapsing-remitting multiple sclerosis: results from the SELECT study. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 419-419.
Tzartos JS, Khan G, Middeldorp J et al. (2012) . Neuropathological study of Epstein Barr-virus infection in the MS brain. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 140-140.
Dobson R, Ramagopalan S, Giovannoni G (2012) . Osteoporosis and fracture risk in multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 243-244.
Giovannoni G, Gold R, Selmaj K et al. (2012) . Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 514-514.
Havrdova E, Gold R, Fox RJ et al. (2012) . Relapses requiring intravenous steroid use and MS-related hospitalisations: findings from the phase 3 DEFINE and CONFIRM studies. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 204-205.
Havrdova E, Gold R, Giovannoni G et al. (2012) . The effect of daclizumab HYP on sustained disability progression in the SELECT trial. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 435-436.
Topping J, Evdoshenko E, Dobson R et al. (2012) . The effects of intrathecal rituximab on biomarkers in MS. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 268-268.
Gafson AR, Giovannoni G (2012) . Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis.Mult Scler vol. 18, (10) 1509-1511.
10.1177/1352458512438117
Dobson R, Topping J, Davis A et al. (2012) . Urinary and CSF biomarkers in multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 502-503.
Gold R, Kappos L, Arnold DL et al. (2012) . Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis.NEW ENGLAND JOURNAL OF MEDICINE vol. 367, (12) 1098-1107.
10.1056/NEJMoa1114287
Pakpoor J, Handel AE, Giovannoni G et al. (2012) . Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine.PLoS ONE vol. 7, (9)
10.1371/journal.pone.0045295
Tzartos J, Khan G, Cruz-Sadaba M et al. (2012) . Association of innate immune activation with latent Epstein - Barr virus infection in active multiple sclerosis lesions. IMMUNOLOGY. vol. 137, 51-51.
Bar-Or A, Gold R, Kappos L et al. (2012) . Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the DEFINE study. EUROPEAN JOURNAL OF NEUROLOGY. vol. 19, 356-356.
Lycke J, Arnold D, Cohen J et al. (2012) . Lymphocyte subset dynamics following alemtuzumab administration in the CARE-MS I trial. EUROPEAN JOURNAL OF NEUROLOGY. vol. 19, 89-89.
CALADO MARTA MS, giovannoni (2012) . ‘What does it mean to have MS? - chapter.Multiple Sclerosis, Oxford University Press (United Kingdom),
Disanto G, Sandve GK, Berlanga-Taylor AJ et al. (2012) . Vitamin D receptor binding, chromatin states and association with multiple sclerosis.Hum Mol Genet vol. 21, (16) 3575-3586.
10.1093/hmg/dds189
Raffel JB, Hunt D, Topping J et al. (2012) . Assay selection affects John Cunningham virus serostatus classification in multiple sclerosis.Ann Neurol vol. 72, (2) 295-296.
10.1002/ana.23629
Marta M, Giovannoni G (2012) . Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon.CNS Neurol Disord Drug Targets vol. 11, (5) 610-623.
10.2174/187152712801661301
http://qmro.qmul.ac.uk/xmlui/handle/123456789/15743
Disanto G, Chaplin G, Morahan JM et al. (2012) . Month of birth, vitamin D and risk of immune-mediated disease: a case control study.BMC Med vol. 10,
10.1186/1741-7015-10-69
http://qmro.qmul.ac.uk/xmlui/handle/123456789/5159
Giovannoni G, Southam E, Waubant E (2012) . Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Mult Scler vol. 18, (7) 932-946.
10.1177/1352458511433302
Giovannoni G, Gold R, Kappos L et al. (2012) . Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with BG-12: findings from the DEFINE study. JOURNAL OF NEUROLOGY. vol. 259, S106-S106.
Gnanapavan S, Grant D, Pryce G et al. (2012) . Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis.Autoimmunity vol. 45, (4) 298-303.
10.3109/08916934.2012.654865
Leite MI, Coutinho E, Lana-Peixoto M et al. (2012) . Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.Neurology vol. 78, (20) 1601-1607.
10.1212/WNL.0b013e31825644ff
http://qmro.qmul.ac.uk/xmlui/handle/123456789/14911
Weinstock-Guttman B, Galetta SL, Giovannoni G et al. (2012) . Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.JOURNAL OF NEUROLOGY vol. 259, (5) 898-905.
10.1007/s00415-011-6275-7
Nicholson TRJ, Ferdinando S, Krishnaiah RB et al. (2012) . Prevalence of anti-basal ganglia antibodies in adult obsessive compulsive disorder: cross-sectional study.BRITISH JOURNAL OF PSYCHIATRY vol. 200, (5) 381-386.
10.1192/bjp.bp.111.092007
Dobson R, Ramagopalan S, Giovannoni G (2012) . The effect of gender in clinically isolated syndrome (CIS): a meta-analysis.Mult Scler vol. 18, (5) 600-604.
10.1177/1352458511426740
Gold R, Giovannoni G, Selmaj K et al. (2012) . A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial. NEUROLOGY. vol. 78,
Giovannoni G, Gold R, Kappos L et al. (2012) . BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study. NEUROLOGY. vol. 78,
Farrell RA, Marta M, Gaeguta AJ et al. (2012) . Development of resistance to biologic therapies with reference to IFN-β.Rheumatology (Oxford) vol. 51, (4) 590-599.
10.1093/rheumatology/ker445
Arnold D, Brinar V, Cohen J et al. (2012) . Effect of Alemtuzumab vs. Rebif (R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study. NEUROLOGY. vol. 78,
Bar-Or A, Gold R, Kappos L et al. (2012) . Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study. NEUROLOGY. vol. 78,
Arnold D, Gold R, Kappos L et al. (2012) . Effect of BG-12 on Brain Atrophy and Lesions Volume: MRI Results from the DEFINE Study during First and Second Year of Treatment. NEUROLOGY. vol. 78,
Arnold D, Gold R, Kappos L et al. (2012) . Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study. NEUROLOGY. vol. 78,
agarwal S, Kappos L, Gold R et al. (2012) . Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study. NEUROLOGY. vol. 78,
Coles A, Brinar V, Arnold D et al. (2012) . Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naive Patients. NEUROLOGY. vol. 78,
Stubinski B, Rocak S, Giovannoni G (2012) . Efficacy, Tolerability and Immunogenicity of the Serum-Free Formulation of Subcutaneous Interferon Beta-1a: Findings of Clinical Trials in Patients with Multiple Sclerosis or with a First Clinical Demyelinating Event. MULTIPLE SCLEROSIS JOURNAL. vol. 18, 536-536.
Giovannoni G (2012) . Emerging disease modifying treatments-A therapeutics update from ECTRIMS/ACTRIMS, Amsterdam, 2011.Mult Scler Relat Disord vol. 1, (2) 56-58.
10.1016/j.msard.2012.01.004
Selmaj K, Arnold D, Brinar V et al. (2012) . Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif (R) in Multiple Sclerosis I (CARE-MS I). NEUROLOGY. vol. 78,
Havrdova E, Arnold D, Cohen J et al. (2012) . Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis I (CARE-MS I). NEUROLOGY. vol. 78,
Fox E, Arnold D, Brinar V et al. (2012) . Relapse Outcomes with Alemtuzumab vs. Rebif (R) in Treatment-Naive Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints. NEUROLOGY. vol. 78,
Baker D, Pryce G, Jackson SJ et al. (2012) . The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.Mult Scler Relat Disord vol. 1, (2) 64-75.
10.1016/j.msard.2011.11.001
Disanto G, Morahan JM, Barnett MH et al. (2012) . The evidence for a role of B cells in multiple sclerosis.Neurology vol. 78, (11) 823-832.
10.1212/WNL.0b013e318249f6f0
Disanto G, Sandve GK, Berlanga-Taylor AJ et al. (2012) . Genomic Regions Associated with Multiple Sclerosis Are Active in B Cells.PLOS ONE vol. 7, (3) Article ARTN e32281,
10.1371/journal.pone.0032281
http://qmro.qmul.ac.uk/xmlui/handle/123456789/4924
Noyce A, Silveira-Moriyama L, Lees AJ et al. (2012) . A PILOT STUDY OF AN ALGORITHM DESIGNED TO IDENTIFY PARKINSON'S DISEASE IN THE EARLY, NON-MOTOR PHASE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2011-301993.161
Noyce A, Bestwick J, Hawkes CH et al. (2012) . AN ALGORITHM TO IDENTIFY INDIVIDUALS AT HIGH-RISK OF PARKINSON'S DISEASE IN THE COMMUNITY. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2011-301993.162
Dobson R, Meier UC, Schmierer K et al. (2012) . DO SIBLINGS OF PEOPLE WITH MULTIPLE SCLEROSIS (MS) HAVE MARKERS OF MS RISK?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2011-301993.173
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7015
Hill-Cawthorne GA, Button T, Tuohy O et al. (2012) . Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY vol. 83, (3) 298-304.
10.1136/jnnp-2011-300826
Raffel J, Dobson R, Giovannoni G (2012) . THE EFFECT OF NATALIZUMAB AND INTERFERON-beta ON URINARY FREE LIGHT CHAINS AND ANTI-EBV NUCLEAR ANTIGEN-1 ANTIBODIES IN RELAPSING REMITTING MULTIPLE SCLEROSIS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2011-301993.190
Noyce A, Treacy C, Budu C et al. (2012) . THE NEW BRADYKINESIA AKINESIA INCOORDINATION (BRAIN) TEST: AN ONLINE TEST OF UPPER LIMB MOVEMENT. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2011-301993.160
Dobson R, Giovannoni G (2012) . WHY CAN'T I WIN ANY MORE?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 83,
10.1136/jnnp-2011-301993.200
Giovannoni G, Rhoades RW (2012) . Individualizing treatment goals and interventions for people with MS.Curr Opin Neurol vol. 25 Suppl, S20-S27.
10.1097/01.wco.0000413321.32834.aa
Sorensen PS, Bertolotto A, Edan G et al. (2012) . Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.MULTIPLE SCLEROSIS JOURNAL vol. 18, (2) 143-152.
10.1177/1352458511435105
Tzartos JS, Khan G, Vossenkamper A et al. (2012) . Association of innate immune activation with latent Epstein-Barr virus in active MS lesions.Neurology vol. 78, (1) 15-23.
10.1212/WNL.0b013e31823ed057
Watson CT, Disanto G, Sandve GK et al. (2012) . Age-associated hyper-methylated regions in the human brain overlap with bivalent chromatin domains.PLoS One vol. 7, (9)
10.1371/journal.pone.0043840
http://qmro.qmul.ac.uk/xmlui/handle/123456789/5430
Rammohan K, Giovannoni G, Comi G et al. (2012) . Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.Mult Scler Relat Disord vol. 1, (1) 49-54.
10.1016/j.msard.2011.08.006
Watson CT, Disanto G, Breden F et al. (2012) . Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs.Sci Rep vol. 2,
10.1038/srep00770
Sato DK, Nakashima I, Fukazawa T et al. (2012) . Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients.Tohoku J Exp Med vol. 228, (2) 85-92.
10.1620/tjem.228.85
Al-Izki S, Pryce G, O'Neill JK et al. (2012) . Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse.Mult Scler Relat Disord vol. 1, (1) 29-38.
10.1016/j.msard.2011.09.001
Ragnedda G, Disanto G, Giovannoni G et al. (2012) . Protein-protein interaction analysis highlights additional loci of interest for multiple sclerosis.PLoS One vol. 7, (10)
10.1371/journal.pone.0046730
http://qmro.qmul.ac.uk/xmlui/handle/123456789/5429
Ali S, Paracha N, Cook S et al. (2012) . Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study.Clin Drug Investig vol. 32, (1) 15-27.
10.2165/11593310-000000000-00000
Ali S, Paracha N, Cook S et al. (2012) . Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.Clin Drug Investig vol. 32, (1) 15-27.
10.2165/11593310-000000000-00000
Disanto G, Morahan JM, Lacey MV et al. (2012) . Seasonal distribution of psychiatric births in England.PLoS One vol. 7, (4)
10.1371/journal.pone.0034866
http://qmro.qmul.ac.uk/xmlui/handle/123456789/4927
Giovannoni G (2012) . The REFLEX study: a missed opportunity?.Lancet Neurol vol. 11, (1) 22-24.
10.1016/S1474-4422(11)70282-4
Gafson A, Giovannoni G, Hawkes CH (2012) . The diagnostic criteria for multiple sclerosis: From Charcot to McDonald.Mult Scler Relat Disord vol. 1, (1) 9-14.
10.1016/j.msard.2011.08.002
Noyce AJ, Treacy C, Budu C et al. (2012) . The new Bradykinesia Akinesia Incoordination (BRAIN) test: preliminary data from an online test of upper limb movement.Mov Disord vol. 27, (1) 157-158.
10.1002/mds.23947
Meier UC, Giovannoni G, Tzartos J et al. (2012) . Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?.Clin. Exp. Immunol vol. 167, (1) 1-6.
10.1111/j.1365-2249.2011.04446.x
Cook SD, Dhib-Jalbut S, Dowling P et al. (2012) . Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.Int J MS Care vol. 14, (3) 105-114.
10.7224/1537-2073-14.3.105
Tzartos JS, Khan G, Vossenkamper A et al. (2011) . Association of innate immune activation with latent Epstein Barr virus in active MS lesions.Neurology vol. 78, (1) 15-23.
10.1212/WNL.0b013e31823ed057
Dobson R, Meier UC, Marta M et al. (2011) . Vitamin D deficiency - do we follow our own advice?.CLINICAL MEDICINE vol. 11, (6) 521-523.
10.7861/clinmedicine.11-6-521
Farrell RA, Espasandin M, Lakdawala N et al. (2011) . Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.Mult Scler vol. 17, (11) 1333-1340.
10.1177/1352458511412654
Disanto G, Handel AE, Morahan JM et al. (2011) . Vitamin D and multiple sclerosis hospital admissions in Scotland.QJM vol. 104, (11) 1001-1003.
10.1093/qjmed/hcr101
Giovannoni G, Gold R, Selmaj K et al. (2011) . A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial.MULTIPLE SCLEROSIS JOURNAL vol. 17, S508-S509.
Thomson A, Espasandin M, Denholm T et al. (2011) . Analysing and redesigning the outpatient experience for people with multiple sclerosis.MULTIPLE SCLEROSIS JOURNAL vol. 17, S486-S486.
Kappos L, Gold R, Arnold D et al. (2011) . BG-12 effects on patient-reported outcomes in relapsing-remitting multiple sclerosis: results from the DEFINE study.MULTIPLE SCLEROSIS JOURNAL vol. 17, S488-S489.
Gold R, Kappos L, Bar-Or A et al. (2011) . Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial.MULTIPLE SCLEROSIS JOURNAL vol. 17, S34-S34.
Dobson R, Meier UC, Schmierer K et al. (2011) . Do siblings have markers of multiple sclerosis risk?.MULTIPLE SCLEROSIS JOURNAL vol. 17, S86-S86.
Coles A, Brinar V, Arnold DL et al. (2011) . Efficacy and safety results from CARE-MS I: a phase 3 study comparing alemtuzumab and interferon-beta-1a.MULTIPLE SCLEROSIS JOURNAL vol. 17, S510-S510.
Arnold D, Gold R, Bar-Or A et al. (2011) . Efficacy on MRI endpoints of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial.MULTIPLE SCLEROSIS JOURNAL vol. 17, S369-S370.
Graves RS, Pryce G, Cabranes A et al. (2011) . Fatty acid amide hydrolase as a target for neuroprotection.MULTIPLE SCLEROSIS JOURNAL vol. 17, S431-S431.
Jackson S, Giovannoni G, Baker D (2011) . Fingolimod (FTY720) modulates microglial activation to augment markers of remyelination.MULTIPLE SCLEROSIS JOURNAL vol. 17, S210-S210.
Ramagopalan S, Ebers G, Meier U et al. (2011) . Identification of Epstein-Barr Virus associated epigenetic changes and association with multiple sclerosis.MULTIPLE SCLEROSIS JOURNAL vol. 17, S10-S10.
Tzartos JS, Khan G, Cruz-Sadaba M et al. (2011) . Innate immune activation is associated with latent Epstein-Barr virus infection in active MS lesions.MULTIPLE SCLEROSIS JOURNAL vol. 17, S350-S350.
Giovannoni G, Sorensen PS, Butzkueven H et al. (2011) . Mitigating severe lymphopenia: post hoc analysis of data from the 96-week CLARITY study.MULTIPLE SCLEROSIS JOURNAL vol. 17, S454-S455.
Lidster K, Jackson S, Coffey P et al. (2011) . Neuroprotection in a novel optic neuritis model.MULTIPLE SCLEROSIS JOURNAL vol. 17, S435-S435.
Selmaj K, Gold R, Kappos L et al. (2011) . Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis.MULTIPLE SCLEROSIS JOURNAL vol. 17, S451-S451.
Al-Izki S, Pryce G, Amor S et al. (2011) . Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis.MULTIPLE SCLEROSIS JOURNAL vol. 17, S209-S210.
Pryce G, Visintin C, Lutz B et al. (2011) . Selective targeting of spasticity by CNS-excluded cannabinoids.MULTIPLE SCLEROSIS JOURNAL vol. 17, S247-S247.
Hadavi S, Noyce AJ, Leslie RD et al. (2011) . Stiff person syndrome.Pract Neurol vol. 11, (5) 272-282.
10.1136/practneurol-2011-000071
Gnanapavan S, Vincent A, Giovannoni G (2011) . Surviving stiff-person syndrome: a case report.J NEUROL vol. 258, (10) 1898-1900.
10.1007/s00415-011-6015-z
Baker D, Pryce G, Visintin C et al. (2011) . VSN16R a novel agent for the control of spasticity.MULTIPLE SCLEROSIS JOURNAL vol. 17, S243-S243.
Maruszak H, Brew BJ, Giovannoni G et al. (2011) . Could antiretroviral drugs be effective in multiple sclerosis? A case report.Eur J Neurol vol. 18, (9) e110-e111.
10.1111/j.1468-1331.2011.03430.x
Tumani H, Deisenhammer F, Giovannoni G et al. (2011) . Revised McDonald Criteria: The Persisting Importance of Cerebrospinal Fluid Analysis.ANN NEUROL vol. 70, (3) 520-520.
10.1002/ana.22508
Disanto G, Meier U, Giovannoni G et al. (2011) . Vitamin D: a link between Epstein-Barr virus and multiple sclerosis development?.EXPERT REV NEUROTHER vol. 11, (9) 1221-1224.
10.1586/ERN.11.97
Al-Izki S, Pryce G, Jackson SJ et al. (2011) . Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.Mult Scler vol. 17, (8) 939-948.
10.1177/1352458511400476
Phillips JT, Giovannoni G, Lublin FD et al. (2011) . Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.MULT SCLER J vol. 17, (8) 970-979.
10.1177/1352458511399611
Jackson SJ, Giovannoni G, Baker D (2011) . Fingolimod modulates microglial activation to augment markers of remyelination.J Neuroinflammation vol. 8,
10.1186/1742-2094-8-76
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7825
Ramagopalan SV, Hoang U, Seagroatt V et al. (2011) . Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study.J NEUROL NEUROSUR PS vol. 82, (6) 682-687.
10.1136/jnnp.2010.232108
Giovannoni G (2011) . CSF markers. JOURNAL OF NEUROLOGY. vol. 258, 9-9.
Cook S, Comi G, Giovannoni G et al. (2011) . Cladribine tablets in patients who had failed prior treatment with injectable disease-modifying drugs for relapsing-remitting multiple sclerosis: evaluation of treatment effect in the CLARITY study. JOURNAL OF NEUROLOGY. vol. 258, 260-260.
Rammohan K, Comi G, Cook S et al. (2011) . Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study. JOURNAL OF NEUROLOGY. vol. 258, 21-21.
Giovannoni G (2011) . Epstein-Barr Virus and MS.Int MS J vol. 17, (2) 44-49.
Rieckmann P, Sorensen PS, Comi G et al. (2011) . Exploring correlations between changes in lymphocyte counts and clinical/magnetic resonance imaging outcomes in cladribine-treated patients with relapsing-remitting multiple sclerosis: analyses from the double-blind, 96-week CLARITY study. JOURNAL OF NEUROLOGY. vol. 258, 48-48.
Giovannoni G (2011) . Promising emerging therapies for multiple sclerosis.Neurol Clin vol. 29, (2) 435-448.
10.1016/j.ncl.2011.01.003
Cook S, Vermersch P, Comi G et al. (2011) . Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.MULT SCLER J vol. 17, (5) 578-593.
10.1177/1352458510391344
Rammohan K, Comi G, Cook S et al. (2011) . Safety of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study. JOURNAL OF NEUROLOGY. vol. 258, 259-259.
Vermersch P, Comi G, Cook S et al. (2011) . Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study. JOURNAL OF NEUROLOGY. vol. 258, 259-259.
Giovannoni G, Nath A (2011) . After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage.Neurology vol. 76, (14) 1200-1201.
10.1212/WNL.0b013e3182143345
Meager A, Dolman C, Dilger P et al. (2011) . An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta Products.J INTERF CYTOK RES vol. 31, (4) 383-392.
10.1089/jir.2010.0113
Ramagopalan SV, Handel AE, Giovannoni G et al. (2011) . Relationship of UV exposure to prevalence of multiple sclerosis in England.NEUROLOGY vol. 76, (16) 1410-1414.
10.1212/WNL.0b013e318216715e
Ramagopalan SV, Meier UC, Conacher M et al. (2011) . Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis.Arch Neurol vol. 68, (4) 469-472.
10.1001/archneurol.2011.48
Giovannoni G, Cook S, Rammohan K et al. (2011) . Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.Lancet Neurol vol. 10, (4) 329-337.
10.1016/S1474-4422(11)70023-0
Giovannoni G (2011) . Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis.MULT SCLER J vol. 17, (3) 259-261.
10.1177/1352458511399799
Banwell B, Bar-Or A, Giovannoni G et al. (2011) . Therapies for multiple sclerosis: considerations in the pediatric patient.NAT REV NEUROL vol. 7, (2) 109-122.
10.1038/nrneurol.2010.198
Maghzi AH, Marta M, Bosca I et al. (2011) . Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?.Pathophysiology vol. 18, (1) 13-20.
10.1016/j.pathophys.2010.04.003
Handel AE, Williamson AJ, Disanto G et al. (2011) . Smoking and Multiple Sclerosis: An Updated Meta-Analysis.PLOS ONE vol. 6, (1) Article e16149,
10.1371/journal.pone.0016149
http://qmro.qmul.ac.uk/xmlui/handle/123456789/5463
Marta M, Santos E, Coutinho E et al. (2011) . INCREASED SERUM IL-8 LEVELS IN BEHCET DISEASE THAN NEUROBEHCET SYNDROME. CLIN EXP RHEUMATOL. vol. 29, 173-173.
Meier UC, Giovannoni G (2011) . More to come: humoral immune responses in MS.Journal of Neuroimmunology vol. 240-241, 13-21.
10.1016/j.jneuroim.2011.09.009
Marta M, Santos E, Coutinho E et al. (2011) . VIRAL INFECTIONS IN NEUROBEHCET SYNDROME. CLIN EXP RHEUMATOL. vol. 29, 193-194.
Petzold A, Mondria T, Kuhle J et al. (2010) . Evidence for Acute Neurotoxicity after Chemotherapy.ANN NEUROL vol. 68, (6) 806-815.
10.1002/ana.22169
Dobson R, Feldmann M, Thompson AJ et al. (2010) . INCREASED URINARY FREE IMMUNOGLOBULIN LIGHT CHAIN EXCRETION IN PATIENTS WITH MULTIPLE SCLEROSIS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 81, E57-E57.
10.1136/jnnp.2010.226340.159
Marshall C, Giovannoni G (2010) . PROGRESSIVE ATAXIA WITH UNUSUAL RADIOGRAPHIC FINDINGS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 81, E34-E34.
10.1136/jnnp.2010.226340.68
Ramagopalan SV, Heger A, Berlanga AJ et al. (2010) . A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution.GENOME RES vol. 20, (10) 1352-1360.
10.1101/gr.107920.110
Pollard J, Boundy K, Butzkueven H et al. (2010) . Benefits of the serum-free formulation of interferon beta-1a: Lessons from clinical trials. MULTIPLE SCLEROSIS. vol. 16, 1282-1282.
Farrell RA, Giovannoni G (2010) . Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis.J INTERF CYTOK RES vol. 30, (10) 715-726.
10.1089/jir.2010.0089
Rieckmann P, Giovannoni G, Comi G et al. (2010) . Efficacy of short-course oral therapy with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study. MULTIPLE SCLEROSIS. vol. 16, 1283-1283.
Rieckmann P, Cook S, Comi G et al. (2010) . Safety and tolerability of short-course oral therapy with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study. MULTIPLE SCLEROSIS. vol. 16, 1283-1284.
Handel AE, Williamson AJ, Disanto G et al. (2010) . An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis.PLOS ONE vol. 5, (9) Article e12496,
10.1371/journal.pone.0012496
Giovannoni G, Comi G, Cook S et al. (2010) . Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study. EUROPEAN JOURNAL OF NEUROLOGY. vol. 17, 215-215.
Rieckmann P, Comi G, Cook S et al. (2010) . Consistent efficacy of cladribine tablets across the spectrum of patients with relapsing-remitting multiple sclerosis of differing severity: data from the 96-week, double-blind CLARITY study. EUROPEAN JOURNAL OF NEUROLOGY. vol. 17, 56-56.
Comi G, Cook S, Giovannoni G et al. (2010) . Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study. EUROPEAN JOURNAL OF NEUROLOGY. vol. 17, 485-485.
Handel AE, Handunnetthi L, Giovannoni G et al. (2010) . Genetic and environmental factors and the distribution of multiple sclerosis in Europe.EUR J NEUROL vol. 17, (9) 1210-1214.
10.1111/j.1468-1331.2010.03003.x
Giovannoni G (2010) . The first on the stage: cladribine. EUROPEAN JOURNAL OF NEUROLOGY. vol. 17, 14-14.
Rejdak K, Leary SM, Petzold A et al. (2010) . Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis.MULT SCLER vol. 16, (9) 1066-1072.
10.1177/1352458510375100
Gnanapavan S, Grant D, Illes-Toth E et al. (2010) . Neural cell adhesion molecule--description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders.J Neuroimmunol vol. 225, (1-2) 118-122.
10.1016/j.jneuroim.2010.04.020
Ramagopalan SV, Hanwell HEC, Giovannoni G et al. (2010) . Vitamin D-Dependent Rickets, HIA-DRB1, and the Risk of Multiple Sclerosis.ARCH NEUROL-CHICAGO vol. 67, (8) 1034-1035.
10.1001/archneurol.2010.182
Giovannoni G (2010) . CSF GFAP: Volcanic ash from anti-aquaporin-4 antibody-mediated destruction of astrocytes.Neurology vol. 75, (3) 200-201.
10.1212/WNL.0b013e3181e8e92d
Ramagopalan SV, Dobson R, Meier UC et al. (2010) . Multiple sclerosis: risk factors, prodromes, and potential causal pathways.Lancet Neurol vol. 9, (7) 727-739.
10.1016/S1474-4422(10)70094-6
Polman CH, Bertolotto A, Deisenhammer F et al. (2010) . Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.LANCET NEUROL vol. 9, (7) 740-750.
10.1016/S1474-4422(10)70103-4
Giovannoni G, Comi G, Cook S et al. (2010) . Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study. JOURNAL OF NEUROLOGY. vol. 257, S21-S21.
Rieckmann P, Comi G, Cook S et al. (2010) . Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study. JOURNAL OF NEUROLOGY. vol. 257, S142-S143.
Sorensen PS, Rieckmann P, Comi G et al. (2010) . Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis. JOURNAL OF NEUROLOGY. vol. 257, S143-S143.
Giovannoni G, Cook S, Sorensen PS et al. (2010) . Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis REPLY.NEW ENGL J MED vol. 362, (18) 1739-1740.
Peferoen LAN, Lamers F, Lodder LNR et al. (2010) . Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis.BRAIN vol. 133, Article e137,
10.1093/brain/awp296
Ramagopalan SV, Dyment DA, Giovannoni G et al. (2010) . HLA-DRB1*15, Low Infant Sibling Exposure, and Multiple Sclerosis Gene-Environment Interaction.ANN NEUROL vol. 67, (5) 694-695.
10.1002/ana.21900
Hawkes CH, Giovannoni G (2010) . The McDonald Criteria for Multiple Sclerosis: time for clarification.Mult Scler vol. 16, (5) 566-575.
10.1177/1352458510362441
Khaleeli Z, Healy DG, Briddon A et al. (2010) . Lesson of the Week Copper deficiency as a treatable cause of poor balance.BRIT MED J vol. 340, Article c508,
10.1136/bmj.c508
Clifford DB, DeLuca A, Simpson DM et al. (2010) . Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.LANCET NEUROL vol. 9, (4) 438-446.
10.1016/S1474-4422(10)70028-4
Guimond C, Dyment DA, Ramagopalan SV et al. (2010) . Prevalence of MS in Iranian Immigrants to British Columbia, Canada.J NEUROL vol. 257, (4) 667-668.
10.1007/s00415-009-5417-7
Dobson R, Miller RF, Palmer HE et al. (2010) . Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis.J Neuroimmunol vol. 220, (1-2) 99-103.
10.1016/j.jneuroim.2010.01.012
Giovannoni G (2010) . Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the 'Spinal Tap'.Mult Scler vol. 16, (3) 285-286.
10.1177/1352458510361358
Handel AE, Giovannoni G, Ebers GC et al. (2010) . Environmental factors and their timing in adult-onset multiple sclerosis.NAT REV NEUROL vol. 6, (3) 156-166.
10.1038/nrneurol.2010.1
Giovannoni G, Comi G, Cook S et al. (2010) . A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.N Engl J Med vol. 362, (5) 416-426.
10.1056/NEJMoa0902533
Teunissen CE, Tumani HT, Bennett JL et al. (2010) . Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'.MULT SCLER vol. 16, (2) 129-132.
10.1177/1352458509356368
Petzold A, Altintas A, Laura C et al. (2010) . Neurofilament ELISA validation.J IMMUNOL METHODS vol. 352, (1-2) 23-31.
10.1016/j.jim.2009.09.014
Teunissen CE, Petzold A, Bennett JL et al. (2010) . A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking.LABORATORIUMSMEDIZIN vol. 34, (1) 1-12.
10.1515/JLM.2010.001
Ramagopalan SV, Sadovnick AD, Ebers GC et al. (2010) . Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis.MULT SCLER vol. 16, (1) 127-128.
10.1177/1352458509350313
Rolls AES, Giovannoni G, Constantinescu CS et al. (2010) . Multiple Sclerosis, Lymphoma and Nasopharyngeal Carcinoma: The Central Role of Epstein-Barr Virus?.EUR NEUROL vol. 63, (1) 29-35.
10.1159/000260902
Rejdak K, Jackson S, Giovannoni G (2010) . Multiple sclerosis: a practical overview for clinicians.Br Med Bull vol. 95, 79-104.
10.1093/bmb/ldq017
Ramagopalan SV, Link J, Byrnes JK et al. (2009) . HLA-DRB1 and month of birth in multiple sclerosis.NEUROLOGY vol. 73, (24) 2107-2111.
10.1212/WNL.0b013e3181c679f3
Teunissen CE, Petzold A, Bennett JL et al. (2009) . A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.NEUROLOGY vol. 73, (22) 1914-1922.
10.1212/WNL.0b013e3181c47cc2
Ramagopalan SV, Giovannoni G (2009) . Can we predict multiple sclerosis?.Lancet Neurol vol. 8, (12) 1077-1079.
10.1016/S1474-4422(09)70273-X
Martino D, Defazio G, Giovannoni G (2009) . The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder.J PSYCHOSOM RES vol. 67, (6) 547-557.
10.1016/j.jpsychores.2009.07.004
Schrag A, Gilbert R, Giovannoni G et al. (2009) . Streptococcal infection, Tourette syndrome, and OCD: is there a connection?.Neurology vol. 73, (16) 1256-1263.
10.1212/WNL.0b013e3181bd10fd
Giovannoni G, Comi G, Cook S et al. (2009) . Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 285, S114-S114.
Giovannoni G, De Stefano N, Migliaccio M (2009) . Development of a new formulation of subcutaneous interferon beta-1a for relapsing-remitting multiple sclerosis: efficacy, safety and immunogenicity results from a comprehensive pre-clinical and clinical trial series. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 285, S204-S204.
Munschauer F, Giovannoni G, O'Connor PW et al. (2009) . Effects of natalizumab treatment on sustained improvement in physical disability and quality of life in patients with relapsing multiple sclerosis. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 285, S109-S109.
Comi G, Cook S, Giovannoni G et al. (2009) . MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 285, S114-S114.
Cook S, Vermersch P, Comi G et al. (2009) . Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 285, S206-S206.
Petzold A, Mondria T, Kuhle J et al. (2009) . Acute treatment related neurotoxicity in secondary progressive multiple sclerosis. MULTIPLE SCLEROSIS. vol. 15, S274-S274.
Rammohan K, Vermersch P, Comi G et al. (2009) . Cladribine tablets produce sustained improvements in relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. MULTIPLE SCLEROSIS. vol. 15, S249-S249.
Giovannoni G, Comi G, Cook S et al. (2009) . Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis. MULTIPLE SCLEROSIS. vol. 15, S136-S137.
Giovannoni G, Comi G, Cook S et al. (2009) . Disease-free status achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis. MULTIPLE SCLEROSIS. vol. 15, S137-S137.
Vermersch P, Comi G, Cook S et al. (2009) . Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. MULTIPLE SCLEROSIS. vol. 15, S249-S249.
Sorensen PS, Comi G, Cook S et al. (2009) . Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. MULTIPLE SCLEROSIS. vol. 15, S137-S137.
Rieckmann P, Comi G, Cook S et al. (2009) . Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study. MULTIPLE SCLEROSIS. vol. 15, S248-S249.
Batocchi AP, Tavazzi B, Frisullo G et al. (2009) . Increase of uric acid and purine compounds in serum of multiple sclerosis patients. MULTIPLE SCLEROSIS. vol. 15, S203-S204.
Munschauer F, Giovannoni G, O'Connor PW et al. (2009) . Natalizumab improves disability on the Multiple Sclerosis Functional Composite in a randomised, double-blind, placebo-controlled study of patients with relapsing multiple sclerosis. MULTIPLE SCLEROSIS. vol. 15, S124-S125.
Maghzi AH, Meier U, Holden D et al. (2009) . Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment. MULTIPLE SCLEROSIS. vol. 15, S73-S73.
Cook S, Vermersch P, Comi G et al. (2009) . Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study. MULTIPLE SCLEROSIS. vol. 15, S20-S20.
Tzartos J, Khan G, Vossenkaemper A et al. (2009) . The anti-viral cytokine interferon-alpha is expressed in acute MS lesions and associated with the presence of Epstein-Barr virus infection. MULTIPLE SCLEROSIS. vol. 15, S276-S276.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7098
Farrell R, Worthington V, Creeke P et al. (2009) . What do we do with positive neutralising antibody tests in subjects with MS?. MULTIPLE SCLEROSIS. vol. 15, S242-S242.
Tumani H, Hartung HP, Hemmer B et al. (2009) . Cerebrospinal fluid biomarkers in multiple sclerosis.NEUROBIOL DIS vol. 35, (2) 117-127.
10.1016/j.nbd.2009.04.010
Martino D, Dale RC, Gilbert DL et al. (2009) . Immunopathogenic Mechanisms in Tourette Syndrome: A Critical Review.MOVEMENT DISORD vol. 24, (9) 1267-1279.
10.1002/mds.22504
Farrell RA, Antony D, Wall GR et al. (2009) . Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.NEUROLOGY vol. 73, (1) 32-38.
10.1212/WNL.0b013e3181aa29fe
Al-Izki S, Pryce G, Giovannoni G et al. (2009) . Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography.Mult Scler vol. 15, (7) 795-801.
10.1177/1352458509104594
Amorini AM, Petzold A, Tavazzi B et al. (2009) . Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients.CLIN BIOCHEM vol. 42, (10-11) 1001-1006.
10.1016/j.clinbiochem.2009.03.020
Deisenhammer F, Egg R, Giovannoni G et al. (2009) . EFNS guidelines on disease-specific CSF investigations.EUR J NEUROL vol. 16, (6) 760-770.
10.1111/j.1468-1331.2009.02595.x
Salvetti M, Giovannoni G, Aloisi F (2009) . Epstein-Barr virus and multiple sclerosis.CURR OPIN NEUROL vol. 22, (3) 201-206.
10.1097/WCO.0b013e32832b4c8d
Giovannoni G, Munschauer F, O'Connor PW et al. (2009) . Natalizumab improves physical disability in patients with relapsing multiple sclerosis. JOURNAL OF NEUROLOGY. vol. 256, S124-S124.
Hutchinson M, Kappos L, Calabresi PA et al. (2009) . The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL ( vol 256, pg 405, 2009).J NEUROL vol. 256, (6) 1035-1037.
10.1007/s00415-009-5183-6
Luk C, Giovannoni G, Williams DR et al. (2009) . Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies.J NEUROSCI METH vol. 180, (1) 34-42.
10.1016/j.jneumeth.2009.02.015
Hu MTM, Butterworth R, Giovannoni G et al. (2009) . Chorea.CLIN MED vol. 9, (2) 188-189.
10.7861/clinmedicine.9-2-188
Havrdova E, Galetta S, Hutchinson M et al. (2009) . Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.LANCET NEUROL vol. 8, (3) 254-260.
10.1016/S1474-4422(09)70021-3
Hutchinson M, Kappos L, Calabresi PA et al. (2009) . The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.J NEUROL vol. 256, (3) 405-415.
10.1007/s00415-009-0093-1
Khatri BO, Man S, Giovannoni G et al. (2009) . Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.NEUROLOGY vol. 72, (5) 402-409.
10.1212/01.wnl.0000341766.59028.9d
Giovannoni G, Barbarash O, Casset-Semanaz F et al. (2009) . Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.Mult Scler vol. 15, (2) 219-228.
10.1177/1352458508097299
Ramagopalan SV, Valdar W, Dyment DA et al. (2009) . Association of Infectious Mononucleosis with Multiple Sclerosis.NEUROEPIDEMIOLOGY vol. 32, (4) 257-262.
10.1159/000201564
Farrell R, Worthington V, Fogell-Hahn A et al. (2009) . DEVELOPING IMPROVED GUIDELINES TO INTERPRET ANTI-IFN NEUTRALISING ANTIBODY TITRES: CORRELATION OF IN VIVO MARKERS OF IFNB; BIOACTIVITY (MXA) WITH LUCIFERASE REPORTER GENE NAB TITRES. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 80, 99-100.
Cavanna AE, Martino D, Orth M et al. (2009) . Neuropsychiatric-developmental model for the expression of tics, pervasive developmental disorder, and schizophreniform symptomatology associated with PANDAS.WORLD J BIOL PSYCHIA vol. 10, (4) 1037-1038.
10.3109/15622970802049767
Monaghan TS, McCarthy AJ, Simister RJ et al. (2009) . OCULAR FLUTTER-OPSOCLONUS-MYOCLONUS SYNDROME IN AN ADULT NEUROLOGICAL PRACTICE: AETIOLOGY AND OUTCOME. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 80, 103-103.
Cohen BA, Oger J, Gagnon A et al. (2008) . The implications of immunogenicity for protein-based multiple sclerosis therapies.J NEUROL SCI vol. 275, (1-2) 7-17.
10.1016/j.jns.2008.08.003
Hampton DW, Anderson J, Pryce G et al. (2008) . An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss.J NEUROIMMUNOL vol. 201, 200-211.
10.1016/j.jneuroim.2008.05.034
Maggiore C, Trillo-Pazos G, Keir G et al. (2008) . Ectopic germinal centres in the brain of people with multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S231-S231.
Farrell R, Antony D, Clark D et al. (2008) . Effect of interferon beta and the development of neutralising antibodies, on reactivation of latent EBV, in patients with multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S229-S229.
Farrell R, Wadhwa M, Worthington V et al. (2008) . Evaluation of activity, aggregation and NAB testing with generic interferon beta products: implications for treating multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S40-S40.
Jackson S, Al-Izik S, Pryce G et al. (2008) . Fingolimod reduces axonal loss in relapsing secondary progressive experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS. vol. 14, S80-S81.
Parkes H, Shorter S, So PW et al. (2008) . High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis. MULTIPLE SCLEROSIS. vol. 14, S86-S87.
Havrdova E, Bates D, Galetta SL et al. (2008) . Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 14, S47-S47.
Munschauer F, Giovannoni G, Lublin F et al. (2008) . Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability. MULTIPLE SCLEROSIS. vol. 14, S167-S168.
Gnanapavan S, Jackson S, Grant D et al. (2008) . Neural cell adhesion molecule as a biomarker of neuro-regeneration in experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS. vol. 14, S281-S281.
Cavanna AE, Draganski B, Martino D et al. (2008) . The neural correlates of premonitory urges in Tourette syndrome. EUROPEAN JOURNAL OF NEUROLOGY. vol. 15, 105-105.
Martino D, Draganski B, Cavanna AE et al. (2008) . Tourette syndrome with and without attention deficit/hyperactivity disorder: a voxel-based morphometry MRI comparison study. EUROPEAN JOURNAL OF NEUROLOGY. vol. 15, 121-122.
Lam R, Farrell R, Aziz T et al. (2008) . Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN beta in multiple sclerosis patients.J IMMUNOL METHODS vol. 336, (2) 113-118.
10.1016/j.jim.2008.03.014
Al-Izki S, Pryce G, Jackson S et al. (2008) . Neuroprotective effects of omega-3 fatty acids in a mouse model of multiple sclerosis. JOURNAL OF NEUROIMMUNOLOGY. vol. 197, 173-173.
Anderson JM, Hampton DW, Patani R et al. (2008) . Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis.BRAIN vol. 131, 1736-1748.
10.1093/brain/awn119
Martino D, Draganski B, Cavanna A et al. (2008) . Anti-basal ganglia antibodies and Tourette's syndrome: a voxel-based morphometry and diffusion tensor imaging study in an adult population.J NEUROL NEUROSUR PS vol. 79, (7) 820-822.
10.1136/jnnp.2007.136689
Giovannoni G (2008) . To test or not to test: NMO-IgG and optic neuritis.NEUROLOGY vol. 70, (23) 2192-2193.
10.1212/01.wnl.0000313843.78606.cd
Confavreux C, Galetta SL, Giovannoni G et al. (2008) . Complete clinical and magnetic resonance imaging response with natalizumab in multiple sclerosis. JOURNAL OF NEUROLOGY. vol. 255, 37-37.
Maggiore C, Trillo-Pazos G, Reynolds R et al. (2008) . Detection of EBV antigens in germinal centres in the brain of people with multiple sclerosis. JOURNAL OF NEUROLOGY. vol. 255, 9-9.
Farrell R, Antony D, Clark D et al. (2008) . Investigation of role of peripheral EBV reactivation in driving multiple sclerosis disease activity as measured by gadolinium enhanced MRI. JOURNAL OF NEUROLOGY. vol. 255, 20-20.
van de Warrenburg BPC, Church AJ, Martino D et al. (2008) . Antineuronal antibodies in Parkinson's disease.MOVEMENT DISORD vol. 23, (7) 958-963.
10.1002/mds.21929
Hintzen RQ, Giovannoni G (2008) . CSF analysis in suspected MS - Do bands aid?.NEUROLOGY vol. 70, (13) 1059-1060.
10.1212/01.wnl.0000306413.29367.82
Farrell R, Anthony D, Clark D et al. (2008) . Is multiple disease activity, as detected by gadolinium enhanced MRI, associated with virological and immunological evidence of EBV reactivation in peripheral blood?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 79, 350-351.
Farrell R, Kapoor R, Leary S et al. (2008) . Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.MULT SCLER vol. 14, (2) 212-218.
10.1177/1352458507082066
Croxford JL, Pryce G, Jackson SJ et al. (2008) . Cannabinoid-mediated neuroprotection, not immuno suppression, may be more relevant to multiple sclerosis.J NEUROIMMUNOL vol. 193, (1-2) 120-129.
10.1016/j.jneuroim.2007.10.024
Rejdak K, Petzold A, Stelmasiak Z et al. (2008) . Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis.MULT SCLER vol. 14, (1) 59-66.
10.1177/1352458507082061
Gani R, Giovannoni G, Bates D et al. (2008) . Cost-effectiveness analyses of natalizumab (Tysabri (R)) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.PHARMACOECONOMICS vol. 26, (7) 617-627.
10.2165/00019053-200826070-00008
Farrell R, Bendtzen K, Bertolotto A et al. (2008) . Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.J INT MED RES vol. 36, (1) 204-208.
Nicholson T, Heyman I, Church A et al. (2007) . Obsessive-compulsive disorder and catatonia can be caused by antibasal ganglia antibodies.COGN BEHAV NEUROL vol. 20, (4) 260-260.
10.1097/WNN.0b013e318158147a
Amor S, Giovannoni G (2007) . Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis - are we there yet?.MULT SCLER vol. 13, (9) 1083-1085.
10.1177/1352458507084431
Driebergen R, Jaber A, Aotonelli M et al. (2007) . Development of Rebif (R) New Formulation for MS treatment: consolidated results from preclinical and phase I studies. MULTIPLE SCLEROSIS. vol. 13, S53-S53.
Rudick RA, Miller D, Hass S et al. (2007) . Health-related quality of life in multiple sclerosis: Effects of Natalizumab.ANN NEUROL vol. 62, (4) 335-346.
10.1002/ana.21163
Herbert J, Kappos L, Giovannoni G et al. (2007) . Impact of natalizumab on multiple sclerosis severity: analysis of patients and subgroups from the AFFIRM study using the Multiple Sclerosis Severity Scale. MULTIPLE SCLEROSIS. vol. 13, S169-S170.
Havrdova E, Giovannoni G, Hutchinson M et al. (2007) . Natalizumab increases the proportion of patients with multiple sclerosis who are disease-free. MULTIPLE SCLEROSIS. vol. 13, S170-S170.
Farrell R, Leary S, Kapoor R et al. (2007) . Neutralising antibodies to interferon beta are associated with loss of efficacy of treatment and reduced side effects. MULTIPLE SCLEROSIS. vol. 13, S59-S59.
GIOVANNONI G, Panzara MA, Kappos L et al. (2007) . The Incidence and Significance of Anti-natalizumab: results from AFFIRM and SENTINEL.Neurology vol. 69, (14) 1391-1403.
10.1212/01.wnl.0000277457.17420.b5
Farrell R, Leary S, Kapoor R et al. (2007) . Evaluation of anti-interferon beta antibodies in subjects with multiple sclerosis attending the national hospital for neurology and neurosurgery, London. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 78, 1038-1038.
Gnanapavan S, Keir G, Grant D et al. (2007) . A sensitive ELISA method for the detection of human Neural Cell Adhesion Molecule (NCAM) in cerebrospinal fluid. JOURNAL OF NEUROCHEMISTRY. vol. 102, 30-30.
Rejdak K, Petzold A, Stelmasiak Z et al. (2007) . Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. vol. 14, 21-22.
Hartung HP, Polman C, Bertolotto A et al. (2007) . Neutralising antibodies to interferon beta in multiple sclerosis - Expert panel report.J NEUROL vol. 254, (7) 827-837.
10.1007/s00415-006-0486-3
Teunissen CE, Killestein J, Giovannoni G (2007) . Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity.BIOMARK MED vol. 1, (1) 111-119.
10.2217/17520363.1.1.111
Giovannoni G, Barbarash O, Casset-Semanaz F et al. (2007) . Immunogenicity and tolerability of an Investigational formulation of interferon-beta 1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.CLIN THER vol. 29, (6) 1128-1145.
10.1016/j.clinthera.2007.06.002
Farrell RA, Giovannoni G (2007) . Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.MULT SCLER vol. 13, (5) 567-577.
10.1177/1352458506073522
Giovannoni G, Ebers G (2007) . Multiple sclerosis: the environment and causation.CURR OPIN NEUROL vol. 20, (3) 261-268.
10.1097/WCO.0b013e32815610c2
Miller DH, Soon D, Fernando KT et al. (2007) . MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.NEUROLOGY vol. 68, (17) 1390-1401.
10.1212/01.wnl.0000260064.77700.fd
Balcer LJ, Galetta SL, Calabresi PA et al. (2007) . Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.NEUROLOGY vol. 68, (16) 1299-1304.
10.1212/01.wnl.0000259521.14704.a8
Maresz K, Pryce G, Ponomarev ED et al. (2007) . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.NAT MED vol. 13, (4) 492-497.
10.1038/nm1561
Chapman MD, Thompson EJ, Candler PM et al. (2007) . Quantitative demonstration of intrathecal synthesis of high affinity immunoglobulin G in herpes simplex encephalitis using affinity-mediated immunoblotting.J NEUROIMMUNOL vol. 185, (1-2) 130-135.
10.1016/j.jneuroim.2007.01.002
Soon D, Altmann DR, Fernando KTM et al. (2007) . A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.J NEUROL vol. 254, (3) 306-314.
10.1007/s00415-006-0356-z
Giovannoni G, O'Connor PW, Havrdova E et al. (2007) . The immunogenicity of natalizumab in patients with multiple sclerosis: Results from the AFFIRM study. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 78, 208-208.
Gnanapavan S, Giovannoni G (2007) . Incorporation of other biomarkers. Neurodegeneration in Multiple Sclerosis. Editors: Filippi, M, Rovaris, M, Comi, G, 183-207.
10.1007/978-88-470-0391-0_15
Marschitz I, Rodl S, Gruber-Sedlmayr U et al. (2007) . Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis.J NEUROL NEUROSUR PS vol. 78, (1) 105-107.
10.1136/jnnp.2006.090555
Rejdak K, Empl M, Giffin NJ et al. (2006) . Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients.EUR J NEUROL vol. 13, (12) 1346-1351.
10.1111/j.1468-1331.2006.01509.x
Hawkes CH, Giovannoni G, Keir G et al. (2006) . Seroprevalence of herpes simplex virus type 2 in multiple sclerosis.ACTA NEUROL SCAND vol. 114, (6) 363-367.
10.1111/j.1600-0404.2006.00677.x
Phillips JT, O'Connor PW, Havrdova E et al. (2006) . Infusion-related hypersensitivity reactions during natalizumab treatment.NEUROLOGY vol. 67, (9) 1717-1718.
10.1212/01.wnl.0000242629.66372.33
Giovannoni G, Chapman MD, Thompson EJ (2006) . The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders.J NEUROIMMUNOL vol. 180, (1-2) 29-32.
10.1016/j.jneuroim.2006.06.033
Giovannoni G, Cutter GR (2006) . Infectious causes of multiple sclerosis.LANCET NEUROL vol. 5, (10) 887-889.
10.1016/S1474-4422(06)70577-4
Petzold A, Mondira T, Keir G et al. (2006) . Accelerated axonal degeneration after bonemarrow transplantation for aggressive multiple sclerosis?. MULTIPLE SCLEROSIS. vol. 12, S216-S216.
Baker D, Croxford JL, Pryce G et al. (2006) . Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis. JOURNAL OF NEUROIMMUNOLOGY. vol. 178, 90-91.
Kallmann BA, Spech E, Kroner A et al. (2006) . Differences in TRADD expression indicated by array analysis discriminates between NIS disease subtypes. JOURNAL OF NEUROIMMUNOLOGY. vol. 178, 202-202.
Deisenhammer F, Bartos A, Egg R et al. (2006) . Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force.EUR J NEUROL vol. 13, (9) 913-922.
10.1111/j.1468-1311.2006.01493.x
Giovannoni G (2006) . Immune tolerance strategies to reverse the development of neutralising anti-interferon-beta antibodies.EUR J NEUROL vol. 13, 302-302.
Petzold A, Eikelenboom M, Keir G et al. (2006) . Impaired energy metabolism and increased lipid peroxidation in multiple sclerosis. MULTIPLE SCLEROSIS. vol. 12, S60-S60.
Farrell RA, Giovannoni G (2006) . Measuring anti-interferon beta neutralising antibodies - A novel cell-based assay. MULTIPLE SCLEROSIS. vol. 12, S205-S205.
Giovannoni G (2006) . Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype.J NEUROL NEUROSUR PS vol. 77, (9) 1001-1002.
10.1136/jnnp.2006.090944
Rejdak K, Leary SM, Petzold A et al. (2006) . Raised urinary neopterin excretion is associated with a better clinical outcome in PP-MS patients treated with interferon beta-1a. MULTIPLE SCLEROSIS. vol. 12, S185-S186.
Hutchinson M, O'Connor PW, Havrdova E et al. (2006) . The effects of natalizumab on disability and health-related quality of life in patients with relapsing MS.EUR J NEUROL vol. 13, 38-38.
Hickman SJ, Sanyal A, Manji H et al. (2006) . "Double whammy" neuropathy: a 37-year-old woman with burning and weakness in both legs.LANCET NEUROL vol. 5, (7) 632-636.
10.1016/S1474-4422(06)70498-7
Karrenbauer VD, Leoni V, Lim ET et al. (2006) . Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis.CLIN NEUROL NEUROSUR vol. 108, (5) 456-460.
10.1016/j.clineuro.2005.07.010
Rejdak K, Petzold A, Bartosik-Psujek H et al. (2006) . Expression of ferritin and S-100B in relation to nitric oxide metabolites in the cerebrospinal fluid of relapsing multiple sclerosis patients. JOURNAL OF NEUROLOGY. vol. 253, 58-59.
Giovannoni G, Cook S, Rieckmann P et al. (2006) . The design of the CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY). JOURNAL OF NEUROLOGY. vol. 253, 99-99.
Candler PM, Dale RC, Griffin S et al. (2006) . Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies.J NEUROL NEUROSUR PS vol. 77, (4) 507-512.
10.1136/jnnp.2005.078105
Polman CH, O'Connor PW, Havrdova E et al. (2006) . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.NEW ENGL J MED vol. 354, (9) 899-910.
10.1056/NEJMoa044397
Dale RC, Candler PM, Church AJ et al. (2006) . Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease.J NEUROIMMUNOL vol. 172, (1-2) 187-197.
10.1016/j.jneuroim.2005.10.014
Martino D, Church AJ, Defazio G et al. (2006) . Corrigendum to: Soluble adhesion molecules in Gilles de la Tourette's syndrome (vol 234, pg 79, 2005).J NEUROL SCI vol. 241, (1-2) 111-+.
10.1016/j.jns.2005.10.012
Giovannoni G (2006) . Multiple sclerosis cerebrospinal fluid biomarkers. DISEASE MARKERS. vol. 22, 187-196.
10.1155/2006/509476
Giovannoni G (2006) . Multiple sclerosis related fatigue.J NEUROL NEUROSUR PS vol. 77, (1) 2-3.
10.1136/jnnp.2005.074948
Hawkes CH, Giovannoni G, Thompson EJ et al. (2006) . Raised prevalence of herpes simplex type-2 antibody in multiple sclerosis. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 77, 131-131.
Giovannoni G, O'Connor P, Havrdova E et al. (2006) . The immunogenicity of natalizumab in patients with multiple sclerosis. CLINICAL IMMUNOLOGY. vol. 119, S116-S116.
10.1016/j.clim.2006.04.264
Petzold A, Eikelenboom MJ, Keir G et al. (2006) . The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers.MULT SCLER vol. 12, (3) 325-328.
10.1191/135248505ms1277oa
Kappos L, O'Connor PW, Havrdova E et al. (2005) . Prognostic indicators of future disease activity in patients with relapsing multiple sclerosis (MS): an analysis from the AFFIRM study. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 238, S75-S75.
Miller DH, O'Connor PW, Havrdova E et al. (2005) . The effects of baseline disease activity on magnetic resonance imaging (MRI) outcomes in the AFFIRM study. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 238, S75-S76.
Galetta SL, O'Connor PW, Havrdova E et al. (2005) . The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 238, S71-S72.
Rejdak K, Leary SM, Stelmasiak Z et al. (2005) . Urinary nitric oxide metabolites and neopterin as markers of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients. JOURNAL OF THE NEUROLOGICAL SCIENCES. vol. 238, S244-S244.
Lim ET, Sellebjerg F, Jensen CV et al. (2005) . Acute axonal damage predicts clinical outcome in patients with multiple sclerosis.MULT SCLER vol. 11, (5) 532-536.
10.1191/1352458505ms1218oa
Dale RC, Heyman I, Giovannoni G et al. (2005) . Incidence of anti-brain antibodies in children with obsessive-compulsive disorder.BRIT J PSYCHIAT vol. 187, 314-319.
10.1192/bjp.187.4.314
Martino D, Branson JA, Church AJ et al. (2005) . Soluble adhesion molecules in acute disseminated encephalomyelitis.PEDIATR NEUROL vol. 33, (4) 255-258.
10.1016/j.pediatrneurol.2005.05.006
Hawkes CH, Giovannoni G, Thompson EJ et al. (2005) . Raised prevalence of herpes simplex type-2 antibody in multiple sclerosis. MULTIPLE SCLEROSIS. vol. 11, S135-S135.
Rejdak K, Petzold A, Chard D et al. (2005) . Raised serum nitric oxide metabolites are related to disease activity in patients with multiple sclerosis: 1-year follow-up study.EUR J NEUROL vol. 12, 320-320.
Soon D, Altmann DR, Barkhof F et al. (2005) . Subtle blood brain barrier leakage in non-enhancing lesions in relapsing multiple sclerosis: multi-centre study of patients in a therapeutic trial. MULTIPLE SCLEROSIS. vol. 11, S2-S2.
Giovannoni G (2005) . What is required for a biomarker to become a good surrogate outcome?. MULTIPLE SCLEROSIS. vol. 11, S10-S11.
Lim ET, Berger T, Reindl M et al. (2005) . Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis.MULT SCLER vol. 11, (4) 492-494.
10.1191/1352458505ms1187sr
Pryce G, O'Neill JK, Croxford JL et al. (2005) . Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.J NEUROIMMUNOL vol. 165, (1-2) 41-52.
10.1016/j.jneuroim.2005.04.009
Martino D, Church AJ, Defazio G et al. (2005) . Soluble adhesion molecules in Gilles de la Tourette's syndrome.J NEUROL SCI vol. 234, (1-2) 79-85.
10.1016/j.jns.2005.03.032
Giovannoni G, Goodman A (2005) . Neutralizing anti-IFN-beta antibodies - How much more evidence do we need to use them in practice?.NEUROLOGY vol. 65, (1) 6-8.
10.1212/01.wnl.0000172080.54415.f1
Giovannoni G (2005) . Anti-neuronal antibodies and movement disorders.J NEUROIMMUNOL vol. 163, (1-2) 5-7.
10.1016/j.jneuroim.2005.03.006
Davies S, Nicholson T, Laura M et al. (2005) . Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis.J NEUROPATH EXP NEUR vol. 64, (5) 371-377.
10.1093/jnen/64.5.371
Martino D, Tanner A, Defazio G et al. (2005) . Tracing Sydenham's chorea: historical documents from a British paediatric hospital.ARCH DIS CHILD vol. 90, (5) 507-511.
10.1136/adc.2004.057679
Lim ET, Schmierer K, Grant D et al. (2005) . A comparison of the immunology and histopathology in post mortem multiple sclerosis brain. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 76, 615-616.
Petzold A, Eikelenboom MJ, Keir G et al. (2005) . Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.J NEUROL NEUROSUR PS vol. 76, (2) 206-211.
10.1136/jnnp.2004.043315
Martino D, Church AJ, Dale RC et al. (2005) . Antibasal ganglia antibodies and PANDAS.MOVEMENT DISORD vol. 20, (1) 116-117.
10.1002/mds.20310
Chapman MD, Hartley JC, Furrows SJ et al. (2005) . Lack of serum oligoclonal antibody responses to Chlamydophila pneumoniae in multiple sclerosis.EUR NEUROL vol. 53, (2) 81-83.
10.1159/000084933
Chapman MD, Hughes LE, Wilson CD et al. (2005) . No evidence for production of intrathecal immunoglobulin g against Acinetobacter or Pseudomonas in multiple sclerosis.EUR NEUROL vol. 53, (1) 27-31.
10.1159/000083715
Rejdak K, Eikelenboom MJ, Petzold A et al. (2004) . CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.NEUROLOGY vol. 63, (8) 1439-1445.
10.1212/01.WNL.0000142043.32578.5D
Edwards MJ, Dale RC, Church AJ et al. (2004) . Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies.MOVEMENT DISORD vol. 19, (10) 1190-1196.
10.1002/mds.20126
Harrison NA, Church A, Nisbet A et al. (2004) . Late recurrences of Sydenham's chorea are not associated with anti-basal ganglia antibodies.J NEUROL NEUROSUR PS vol. 75, (10) 1478-1479.
10.1136/jnnp.2003.030775
Pryce G, Jackson SM, Hankey DRJ et al. (2004) . Cannabinoids are neuroprotective: dissociation of true neuroprotection from protection secondary to immunosuppression. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 78-78.
Pryce G, O'Neill JK, Hankey DRJ et al. (2004) . Immunological tolerance that eliminates relapses, fails to halt secondary progression in a chronic multiple sclerosis model. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 62-62.
Giovannoni G (2004) . Is it time to consider rationalising IFN-beta treatment in individuals with multiple sclerosis?.J NEUROL NEUROSUR PS vol. 75, (9) 1234-1234.
10.1136/jnnp.2004.046342
Zwemmer JNP, Eikelenboom MJ, Kay A et al. (2004) . No association of apoE concentration in CSF with clinical arid MR1 characteristics in MS. MULTIPLE SCLEROSIS. vol. 10, S212-S213.
Giovannoni G (2004) . Optimising MS disease-modifying therapies: antibodies in perspective.J NEUROL vol. 251, 30-35.
10.1007/s00415-004-1505-x
Rejdak K, Leary SM, Nelissen I et al. (2004) . Urinary neopterin is a sensitive marker of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients.EUR J NEUROL vol. 11, 120-120.
Edwards MJ, Trikouli E, Martino D et al. (2004) . Anti-basal ganglia antibodies in patients with atypical dystonia and tics: A prospective study. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 75, 1216-1216.
Martino D, Giovannoni G (2004) . Antibasal ganglia antibodies and their relevance to movement disorders.CURR OPIN NEUROL vol. 17, (4) 425-432.
10.1097/01.wco.0000137532.76491.19
Lim ET, Sellebjerg F, Sorensen TL et al. (2004) . Cerebrospinal fluid neurofilament heavy chain levels in acute optic neuritis and multiple sclerosis patients treated with oral high-dose methylpredinolone. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 75, 1215-1215.
Edwards MJ, Trikouli E, Martino D et al. (2004) . Anti-basal ganglia antibodies in patients with atypical dystonia and tics - A prospective study.NEUROLOGY vol. 63, (1) 156-158.
10.1212/01.WNL.0000131900.71337.C7
Church AJ, Dale RC, Giovannoni G (2004) . Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders?.ARCH DIS CHILD vol. 89, (7) 611-614.
10.1136/adc.2003.031880
Dale RC, Heyman I, Surtees RAH et al. (2004) . Dyskinesias and associated psychiatric disorders following streptococcal infections.ARCH DIS CHILD vol. 89, (7) 604-610.
10.1136/adc.2003.031856
Edwards MJ, Dale RC, Church AJ et al. (2004) . A dystonic syndrome associated with anti-basal ganglia antibodies.J NEUROL NEUROSUR PS vol. 75, (6) 914-916.
10.1136/jnnp.2002.009043
Spech E, Kallmann B, Kroner A et al. (2004) . Gene expression analysis indicates distinct immune pattern in relapsing remitting (RR) and primary progressive (PP) MS disease type. JOURNAL OF NEUROLOGY. vol. 251, 175-175.
Rejdak K, Petzold A, Sharpe MA et al. (2004) . Cerebrospinal fluid nitrite/nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage.J NEUROL SCI vol. 219, (1-2) 71-76.
10.1016/j.jns.2003.12.011
Petzold A, Keir G, Green AJE et al. (2004) . An ELISA for glial fibrillary acidic protein.J IMMUNOL METHODS vol. 287, (1-2) 169-177.
10.1016/j.jim.2004.01.015
Pereira AC, Edwards MJ, Buttery PC et al. (2004) . Choreic syndrome and coeliac disease: A hitherto unrecognised association.MOVEMENT DISORD vol. 19, (4) 478-482.
10.1002/mds.10691
Giovannoni G (2004) . Toward better diagnosis of progressive supranuclear palsy: Cerebrospinal fluid biomarkers. MOVEMENT DISORDERS. vol. 19, 361-362.
Miranda M, Cardoso F, Giovannoni G et al. (2004) . Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies.J NEUROL NEUROSUR PS vol. 75, (2) 327-328.
Giovannoni G, Deisenhammer F (2004) . Neutralising antibodies against interferon beta in multiple sclerosis.LANCET vol. 363, (9403) 166-167.
10.1016/S0140-6736(03)15275-0
Lim ET, Grant D, Pashenkov M et al. (2004) . Cerebrospinal fluid levels of brain specific proteins in optic neuritis.MULT SCLER vol. 10, (3) 261-265.
10.1191/1352458504ms1020oa
Furrows SJ, Hartley JC, Bell J et al. (2004) . Chlamydophila pneumoniae infection of the central nervous system in patients with multiple sclerosis.J NEUROL NEUROSUR PS vol. 75, (1) 152-154.
Dale RC, Church AJ, Surtees RAH et al. (2004) . Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity.BRAIN vol. 127, 21-33.
10.1093/brain/awh008
Deisenhammer F, Giovannoni G (2004) . Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.MULT SCLER J vol. 10, (6)
10.1191/1352458504ms1107xx
Giovannoni G (2004) . Management of secondary-progressive multiple sclerosis.CNS DRUGS vol. 18, (10) 653-669.
10.2165/00023210-200418100-00003
Petzold A, Brassat D, Mas P et al. (2004) . Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis.MULT SCLER vol. 10, (3) 281-283.
10.1191/1352458504ms1021sr
Giovannoni G (2003) . Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. NEUROLOGY. vol. 61, S13-S17.
10.1212/01.WNL.0000092379.75791.5D
Pryce G, Ahmed Z, Hankey DJR et al. (2003) . Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.BRAIN vol. 126, 2191-2202.
10.1093/brain/awg224
Dubois B, Leary SM, Nelissen I et al. (2003) . Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta 1a.J NEUROL vol. 250, (9) 1037-1043.
10.1007/s00415-003-0110-8
Empl M, Redjak K, Giovannoni G et al. (2003) . Urinary nitric oxide metabolites in migraineurs. CEPHALALGIA. vol. 23, 636-637.
Tengah DSNAP, Church A, Giovannoni G et al. (2003) . An anti-spinal antibody in dermatitis herpetiformis patients. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 74, 1180-1180.
Giovannoni G, Dubois BD, Keenan E et al. (2003) . Beta-interferon in multiple sclerosis: An assessment of the ABN stopping criteria in clinical practice. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 74, 1177-1178.
Giovannoni G, Deisenhammer F, Munschauer FE (2003) . Neutralising antibodies to interferon beta - Reply.J NEUROL NEUROSUR PS vol. 74, (8) 1162-1163.
Petzold A, Keir G, Green AJE et al. (2003) . A specific ELISA for measuring neurofilament heavy chain phosphoforms.J IMMUNOL METHODS vol. 278, (1-2) 179-190.
10.1016/S0022-1759(03)00189-3
Dubois BD, Keenan E, Porter BE et al. (2003) . Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre.J NEUROL NEUROSUR PS vol. 74, (7) 946-949.
10.1136/jnnp.74.7.946
Empl M, Giovannoni G (2003) . Nitric oxide and headache: related, but how?.CEPHALALGIA vol. 23, (6) 405-406.
10.1046/j.1468-2982.2003.00575.x
Rejdak K, Petzold A, Sharpe MA et al. (2003) . Cerebrospinal fluid nitrite/nitrate predicts poor outcome in patients with subarachnoid hemorrhage (SAH). JOURNAL OF NEUROCHEMISTRY. vol. 85, 25-25.
10.1046/j.1471-4159.85.s2.18_8.x
Giovannoni G, Baker D (2003) . Inflammatory disorders of the central nervous system.CURR OPIN NEUROL vol. 16, (3) 347-350.
10.1097/01.wco.0000073936.19076.9c
Pryce G, Giovannoni G, Baker D (2003) . Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice.NEUROSCI LETT vol. 341, (2) 164-166.
10.1016/S0304-3940(03)00159-9
Petzold A, Baker D, Pryce G et al. (2003) . Quantification of neurodegeneration by measurement of brain-specific proteins.J NEUROIMMUNOL vol. 138, (1-2) 45-48.
10.1016/S0165-5728(03)00092-4
Baker D, Pryce G, Giovannoni G et al. (2003) . The therapeutic potential of cannabis.LANCET NEUROL vol. 2, (5) 291-298.
10.1016/S1474-4422(03)00381-8
Church AJ, Dale RC, Lees AJ et al. (2003) . Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis.J NEUROL NEUROSUR PS vol. 74, (5) 602-607.
10.1136/jnnp.74.5.602
Rejdak K, Petzold A, Sharpe MA et al. (2003) . Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury.J NEUROL SCI vol. 208, (1-2) 1-7.
10.1016/S0022-510X(02)00412-4
Davies G, Keir G, Thompson EJ et al. (2003) . The clinical significance of an intrathecal monoclonal immunoglobulin band - A follow-up study.NEUROLOGY vol. 60, (7) 1163-1166.
10.1212/01.WNL.0000055864.08740.CB
Church AJ, Dale RC, Cardoso F et al. (2003) . CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome?.J NEUROIMMUNOL vol. 136, (1-2) 149-153.
10.1016/S0165-5728(03)00012-2
Eikelenboom MJ, Petzold A, Lazeron RHC et al. (2003) . Multiple sclerosis - Neurofilament light chain antibodies are correlated to cerebral atrophy.NEUROLOGY vol. 60, (2) 219-223.
10.1212/01.WNL.0000041496.58127.E3
Giovannoni G, Bever CT (2003) . Patients with clinically isolated syndromes suggestive of MS - Does MRI allow earlier diagnosis?.NEUROLOGY vol. 60, (1) 6-7.
10.1212/WNL.60.1.6
Trip SA, Wroe SJ, Davies G et al. (2003) . Primary CNS mantle cell lymphoma associated with an isolated CSF monoclonal IgG band.EUR NEUROL vol. 49, (3) 187-188.
10.1159/000069080
Giovannoni G (2003) . The Yin and Yang of inflammation in multiple sclerosis. EARLY INDICATORS, EARLY TREATMENTS, NEUROPROTECTION IN MULTIPLE SCLEROSIS. Editors: Hommes, OR, Comi, G, 181-189.
Giovannoni G, Munschauer FE, Deisenhammer F (2002) . Neutralising antibodies to interferon beta during the treatment of multiple sclerosis.J NEUROL NEUROSUR PS vol. 73, (5) 465-469.
10.1136/jnnp.73.5.465
Rejdak K, Bartosik-Psujek H, Dobosz B et al. (2002) . Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients.NEUROSCI LETT vol. 331, (1) 63-65.
10.1016/S0304-3940(02)00710-3
Church AJ, Cardoso F, Dale RC et al. (2002) . Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea.NEUROLOGY vol. 59, (2) 227-231.
10.1212/WNL.59.2.227
Petzold A, Eikelenboom MJ, Gveric D et al. (2002) . Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.BRAIN vol. 125, 1462-1473.
10.1093/brain/awh008
Dale RC, Church AJ, Benton S et al. (2002) . Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis.DEV MED CHILD NEUROL vol. 44, (7) 485-489.
10.1111/j.1469-8749.2002.tb00310.x
Dale RC, Church AJ, Surtees RAH et al. (2002) . Post-streptococcal autoimmune neuropsychiatric disease presenting as paroxysmal dystonic choreoathetosis.MOVEMENT DISORD vol. 17, (4) 817-820.
10.1002/mds.10169
Sellebjerg F, Giovannoni G, Hand A et al. (2002) . Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis.J NEUROIMMUNOL vol. 125, (1-2) 198-203.
10.1016/S0165-5728(02)00037-1
Derry C, Dale RC, Thom M et al. (2002) . Unihemispheric cerebral vasculitis mimicking Rasmussen's encephalitis.NEUROLOGY vol. 58, (2) 327-328.
10.1212/WNL.58.2.327
Ramachandran V, Church A, Giovannoni G et al. (2002) . Anti-basal ganglia antibodies are absent in patients with primary blepharospasm.NEUROLOGY vol. 58, (1) 150-150.
10.1212/WNL.58.1.150
Tengah DSNAP, Unsworth DJ, Fry L et al. (2002) . Dermatitis herpetiformis, coeliac disease, and neurological dysfunction.J NEUROL NEUROSUR PS vol. 72, (1) 142-142.
Dale RC, Church AJ, Cardoso F et al. (2001) . Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies.ANN NEUROL vol. 50, (5) 588-595.
10.1002/ana.1250
Giovannoni G, Thorpe J (2001) . Is it multiple sclerosis or not?.NEUROLOGY vol. 57, (8) 1357-1358.
10.1212/WNL.57.8.1357
Giovannoni G, Thompson AJ, Miller DH et al. (2001) . Fatigue is not associated with raised inflammatory markers in multiple sclerosis.NEUROLOGY vol. 57, (4) 676-681.
10.1212/WNL.57.4.676
Giovannoni G (2001) . Human swayback disease: expanding the spectrum of diseases associated with abnormal copper metabolism.J NEUROL vol. 248, (8) 707-707.
10.1007/s004150170119
Giovannoni G, Miller DH, Losseff NA et al. (2001) . Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis.J NEUROL vol. 248, (6) 487-495.
10.1007/s004150170158
Chamoun V, Zeman A, Blennow K et al. (2001) . Haptoglobins as markers of blood-CSF barrier dysfunction: the findings in normal CSF.J NEUROL SCI vol. 182, (2) 117-121.
10.1016/S0022-510X(00)00461-5
Palmer HE, Giovannoni G, Stanford MR et al. (2001) . Urinary neopterin in idiopathic retinal vasculitis.BRIT J OPHTHALMOL vol. 85, (1) 30-33.
10.1136/bjo.85.1.30
Green AJE, Giovannoni G, Hall-Crags MA et al. (2000) . Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease.SEX TRANSM INFECT vol. 76, (6) 443-446.
10.1136/sti.76.6.443
GIOVANNONI G, Cohen JA, Coles AJ et al.. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.Neurology
10.1212/WNL.0000000000003319
http://qmro.qmul.ac.uk/xmlui/handle/123456789/16162
Williams T, Marta M, Giovannoni G. IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension.Practical Neurology vol. 16, (3) 235-239.
10.1136/practneurol-2015-001275
GIOVANNONI G. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.New England Journal of Medicine
10.1056/NEJMoa1601277
GIOVANNONI G. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.New England Journal of Medicine
10.1056/NEJMoa1606468
Giovannoni G, Marta M, Davis A et al.. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.Practical Neurologypractneurol-2015-001-practneurol-2015-001.
10.1136/practneurol-2015-001355
http://qmro.qmul.ac.uk/xmlui/handle/123456789/14950
Return to top